Prognostic and therapeutic challenges in acute coronary syndromes by Rasoul, Saman,
Prognostic and Therapeutic Challenges in
Acute Coronary Syndromes
Saman Rasoul2
Financial support by the Netherlands Heart Foundation and the Zwols
Wetenschapsfonds Isala Klinieken–ZWIK for the publication of this thesis is
gratefully acknowledged. 
The study described in this thesis was supported by a grant of the Netherlands
Heart Foundation (NHF-2003 B277).
Cover design: Nauras
Cover lay-out: U Art Recalme: www.uart.nl 
Printed by: Gildeprint B.V.
ISBN: 90-9021536-0
© 2007, S. Rasoul
All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or
transmitted, in any form or by any means, electronic, mechanical, photocopying, recording,
or otherwise, without the prior permission of the holder of the copyright.RIJKSUNIVERSITEIT GRONINGEN
Prognostic and Therapeutic Challenges in Acute
Coronary Syndromes
Proefschrift
ter verkrijging van het doctoraat in de 
Medische Wetenschappen 
aan de Rijksuniversiteit Groningen 
op gezag van de 
Rector Magnificus, dr. F. Zwarts, 
in het openbaar te verdedigen op 
woensdag 4 april 2007
om 14:45 uur
door
Saman Rasoul
geboren op 01 mei 1972 
te Kirkuk 4
Promotor:  Prof. dr. F. Zijlstra
Copromotores:  Dr J.P. Ottervanger
Dr A.W.J. van ‘t Hof
Beoordelingscommissie:  Prof. dr. H.J.G. Bilo 
                                         Prof. dr. J.J. Piek
                                         Prof. dr. D.J. van VeldhuisenTo Mary, Avesta, Arya and my parents 
 6Contents
7
Contents
Chapter 1
1. General introduction and outline of the thesis.
Chapter 2 
Improvement in early diagnosis and treatment of patients with
acute coronary syndromes
2.1 Are patients with non-ST elevation myocardial infarction
undertreated?
BMC Cardiovasc Disord, In press.
2.2 Primary PCI for ST-elevation myocardial infarction: from
clinical trial to clinical practice.
Submitted.
2.3 Shift towards earlier diagnosis and: Feasibility and benefit of
pre-hospital diagnosis, triage and therapy by paramedics
only in patients who are candidates for primary angioplasty
for acute myocardial infarction.
Am Heart J 2006;1255:e1-5.
2.4      A comparison of dual versus triple antiplatelet therapy in       
         patients with non-ST elevation acute coronary syndrome.      
         Results of the ELISA-2 trial.
    Eur Heart J 2006;27:1401-7.
Chapter 3 
Prognosis 
3.1  External validity of ST-elevation myocardial infarction trials:
The Zwolle studies.  
Catheter Cardiovasc Interv, In press
11
19
33
49
61
79Contents
8
119
131
141
157
167
173
175
3.2  Circumflex artery related acute myocardial infarction: 
limited ECG abnormalities but poor outcome. 
Submitted.
3.3  Predictors of elevated cardiac troponin T on admission in
ST-elevation myocardial infarction.
Ann Clin Biochem 2006;43:281-6.
 
Chapter 4 
Glucose mediated therapeutic options 
4.1  A quantitative analysis of the effect of glucose-insulin-potassium
in acute myocardial infarction.
Neth H J 2006;14:19-23. 
4.2  One-year results of the Glucose-Insulin-Potassium-Study-II
(GIPS-II).
In J Cardiol, In press
4.3  Glucose dysregulation in non-diabetic patients with ST-elevation
myocardial infarction predicts mainly short-term prognosis. 
   Neth J Med, In press
Chapter 5
5  Summary and conclusions.
Chapter 6
6 Samenvatting en conclusies.
Curriculum vitae
List of publications
Dankwoord
91
103
177                                                                                                                     Chapter 1
9
Chapter 1
General Introduction and Outline of the
ThesisChapter 1
11
General Introduction and Outline of the Thesis
Since the 70s of the last century, treatment and prognosis of myocardial infarction
has improved dramatically. In patients with ST-elevation myocardial infarction
(STEMI) treatment with fibrinolytics and more recently primary percutaneous
coronary intervention (PCI) has improved short- and long-term outcome [1-3].  
This temporal change may also be associated with the greater use of guideline
recommended medication and coronary interventions [4-8]. Secondary
prevention, including β-blockers, angiotensin-converting enzyme inhibitors and
statins has further decreased mortality after hospital discharge [9-11].
However, coronary events remain a major cause of death and disability in the
western community and require extensive health care expenditure. Additional
improvement in diagnosis and treatment of acute coronary syndromes may further
improve quality of life and decrease mortality. This improvement may be achieved
by a more rapid
  diagnosis and early risk stratification, to initiate
  as soon
  as
possible reperfusion therapy to limit infarct size, and to treat complications such
as pump failure or life-threatening arrhythmias. 
Reperfusion therapy
Early, effective, and persistent
 recanalization of the infarct related coronary artery
and reperfusion of the myocardium
  are the goals of the treatment in STEMI
[12,13].
 Several clinical trials have shown that primary PCI is more effective than
fibrinolytic therapy (Figure 1) [14-16].
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Figure 1: Primary angioplasty vs. thrombolysis. Pooled analysis of randomized trials. Reproduced
with permission from Eur Heart J [14].General Introduction and outline
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Therefore, according to both the ESC and AHA/ACC guidelines, when primary
PCI is available in a ‘timely’
 fashion and the procedure can be performed by an
‘experienced’
  operator in a ‘large volume’ centre, primary PCI
  should be
considered the preferred reperfusion strategy [12,17].
 
However, results of the randomized trials may be based on selected patients and
may not reflect daily practice. Observational studies should confirm these results,
and also assess whether results of primary PCI have even been improved over
time. 
In order to further improve the outcome of patients with STEMI, pharmacological
pre-treatment e.g. glycoprotein IIb/IIIa inhibitors,
  with the aim to improve initial
patency during transportation
 and before intervention, might be beneficial [18-20].
In addition, several large scale clinical trials have evaluated the effect of metabolic
intervention with glucose-insulin-potassium (GIK) in patients with STEMI with
conflicting results. The DIGAMI-1 [21] and GIPS-1 [22] trial showed beneficial
effects of GIK, but this finding was not confirmed by DIGAMI-II [23], GIPS-II [24]
and CREATE-ECLA-II [25] trials. 
This thesis
This thesis describes several prognostic and therapeutic challenges in patients
with acute coronary syndromes. 
Chapter 2 is focused on general backgrounds and improvement in early
diagnosis and treatment of patients with acute coronary syndromes. In Chapter
2.1  we describe  during an one-year study period,  unselected patients with a
discharge diagnosis of non-ST elevation myocardial infarction (non-STEMI).
These patients are compared with those with a discharge diagnosis of STEMI.
The differences in baseline characteristics, treatment and outcome are described.
Chapter 2.2 is entitled ‘Primary Percutaneous Coronary Intervention for ST-
Elevation Myocardial Infarction: from Clinical Trial to Clinical Practice, and
describes more than a decade experience in Zwolle with primary PCI. It assesses
time-dependent changes in baseline characteristics, concomitant treatment and
prognosis in patients with STEMI treated with primary PCI. Chapter 2.3 describes
the feasibility and benefit of pre-hospital myocardial infarction diagnosis and triage
in the ambulance by paramedics with direct transport to a PCI center and
compares outcome with triage at a referral non-PCI center. Chapter 2.4
addresses the results of the Early or Late Intervention in unStable Angina-2
(ELISA-2) trial in which the effect of dual (aspirin, clopidogrel) was compared to
triple (aspirin, clopidogrel, tirofiban) antiplatelet treatment in non-ST elevationChapter 1
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acute coronary syndrome (NSTE ACS) patients who were all scheduled for early
coronary angiography. The effect of triple antiplatelet treatment on enzymatic
infarct size and initial TIMI flow is described.
Chapter 3 describes several issues related to prognosis after acute myocardial
infarction.  Chapter 3.1 addresses the external validity of clinical trials of
myocardial infarction. In this chapter differences in baseline, management and
outcome between STEMI patients enrolled in a clinical trial or registry versus
those who were not enrolled are evaluated.  Chapter 3.2 describes the difference
in presenting electrocardiogram and outcome between circumflex related
infarction and right coronary artery related infarction. The patient population
consists of unselected consecutive patients with STEMI. Chapter 3.3 is focused
on cardiac troponin T (cTnT) on admission in 444 patients with STEMI. The
predictors of elevated cTnT on admission and its prognostic value are evaluated.
Chapter 4 is focused on  glucose mediated therapeutic options in STEMI.
Chapter 4.1 is a review of the currently available data with regard to the clinical
benefit of high- and low-dose glucose-insulin-potassium (GIK) in patients with
STEMI.  Chapter 4.2 shows the long-term results of the Glucose-Insulin-
Potassium Study-II (GIPS–II). GIPS-II evaluated the effects of GIK in STEMI
patients without signs of heart failure, all treated with reperfusion therapy.
Chapter 4.3 investigates the 30-day and long-term prognostic value of both
admission glucose and chronic glucose dysregulation in non-diabetic patients with
STEMI. General Introduction and outline
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Chapter 2.1
Are Patients with Non-ST Elevation Myocardial Infarction
Undertreated? 
Saman Rasoul, Jan Paul Ottervanger, Jan-Henk E Dambrink, Menko-Jan de
Boer, Jan CA Hoorntje, AT Marcel Gosselink, Felix Zijlstra, Harry
Suryapranata, Arnoud WJ van ‘t Hof
BMC Cardiovasc Disord, In pressAre non-STEMI patients undertreated?                                                                      
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Abstract
Background
The worse prognosis in patients without ST-elevation (non-STEMI) as compared
to patients with ST-elevation myocardial infarction (STEMI), may be due to
treatment differences. We aimed to evaluate the differences in characteristics,
treatment and outcome in patients with non-STEMI versus patients with STEMI in
an unselected population.
Methods
Individual patient data from all patients in our hospital with a discharge diagnosis
of myocardial infarction (MI) between January 2001 and January 2002 were
evaluated. Follow-up data were obtained until December 2004.  Patients were
categorized according to the presenting electrocardiogram into non-STEMI or
STEMI.
Results
A total of 824 patients were discharged with a diagnosis of MI, 29% with non-
STEMI and 71% with STEMI. Patients with non-STEMI were significantly older
and had a higher cardiovascular risk profile. They underwent less frequently
coronary angiography and revascularization and received less often clopidogrel
and ACE-inhibitor on discharge. Long-term mortality was significantly higher in
the non-STEMI patients as compared to STEMI patients, 20% vs. 12%,
respectively, p =0.006. However, multivariate analysis showed that age, diabetes,
previous myocardial infarction and not performing angiography (but not non-
STEMI presentation) were independent and significant predictors of long-term
mortality. 
Conclusion
In an unselected cohort of patients discharged with
  MI, there were significant
differences in baseline characteristics, and (invasive) treatment between STEMI
and non-STEMI. Long-term mortality was also different, but this was due to
differences in baseline characteristics and treatment. More aggressive treatment
may improve outcome in non-STEMI patients.    Chapter 2.1
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Introduction 
Myocardial infarction (MI) is usually categorized into non-ST-elevation
 myocardial
infarction (non-STEMI) and ST-elevation myocardial infarction
 (STEMI). Patients
with STEMI should be treated immediately with reperfusion therapy
  by either
percutanous coronary intervention (PCI) or thrombolysis, if admitted within 12 h of
symptom onset [1-4]. Patients
 with non-STEMI should be stabilized medically and
high-risk patients should be scheduled
 for an early (within days) interventional
strategy [5,6]. 
A previous study has shown that in unselected patients, mortality was significantly
higher in the non-STEMI as compared to STEMI patients [7]. However, in that study
coronary angiography was only performed in 52%, only 70% of the eligible STEMI
patients were treated with reperfusion therapy and no information was available with
regard to the type of reperfusion therapy. The purpose of our study was to evaluate
the baseline characteristics, treatment and prognosis in an unselected consecutive
cohort of non-STEMI versus STEMI patients in a single high-volume centre.
Methods
Population 
From January 2001 to January 2002, individual patient data from all patients with
the discharge diagnosis of acute myocardial infarction (MI) at the Isala klinieken
(Zwolle, The Netherlands) were recorded.  To avoid double inclusion of patients,
only the first admission for MI during the study period was used. 
According to the presenting ECG, patients were categorized as non-STEMI or
STEMI. Patients were diagnosed with non-STEMI if they had ischemic chest pain
classified as Braunwald class 3 and the presence of at least 1 of the following
criteria: (new) ST depression of more than 1 mm in at least 2 ECG leads or a
positive biomarker (cardiac troponin T > 0.05 µg/L, or CK-MB elevation more than
upper limit of normal).  STEMI was defined as chest pain of > 30 minutes duration
and ECG changes with ST segment elevation of > 2 mm in at least 2 precordial
and > 1 mm in the limb leads.  
Data collection and follow-up
We collected the following variables from the patient files:
 age, gender, history of
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction
and discharge medication. Follow-up information was obtained from the patient's
general physician or by direct telephone interview with the patient. Are non-STEMI patients undertreated?                                                                      
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Statistical analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean and categorical data as
percentage, unless otherwise denoted. The analysis of variance and the chi-
square test were appropriately used for continuous and categorical variables
respectively. Cox proportional hazard regression procedure was performed to
estimate the hazard ratio of mortality of the findings. Significant variables
analyzed are reported with their respective Hazard ratio (HR) and 95%
confidence intervals (CI). For all analyses, statistical significance was assumed
when the two tailed probability value was < 0.05.
Results
During the study period, 824 patients were discharged with a diagnosis of MI;
29% categorized as non-STEMI (N = 241) and 71% as STEMI (N= 583). 
Baseline characteristics  
Baseline characteristics are summarized in Table 1. Patients with non-STEMI
were significantly older, more often female, had more often hypertension or a
history of previous myocardial infarction. 
Table 1: Baseline characteristics 
STEMI non-STEMI P-value
Variable                                  (N = 583)                      (N = 241)                                
Age, mean ± SD 63 ± 12 67 ± 12 <0.001
Female gender, n (%) 150/582 (26%) 77/240 (32%) 0.07
Diabetes, n (%) 80/568 (14%) 37/234 (16%) 0.53
Hypertension, n (%) 199/529 (38%) 101/229 (44%) 0.09
Hyperlipidemia, n (%) 126/406 (31%) 76/207 (37%) 0.16
Smoking, n (%) 251/558 (45%) 70/232 (30%) <0.001
Previous MI, n (%)                   81/578 (14%)              45/233 (19%)              0.06     
MI= myocardial infarction Chapter 2.1
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Treatment 
Cardiac catheterization and percutaneous coronary intervention (PCI) were
significantly less often performed in non-STEMI patients (Table 2). Coronary artery
bypass grafting (CABG) was performed more often in the non-STEMI patients.  
Table 2: Treatment and outcome
                                                STEMI                                      non-STEMI                 P-value
CAG, n (%) 541/583 (93%) 189/241 (78%) <0.001
PCI, n (%) 481/583 (83%) 99/241(41%) <0.001
Thrombolysis, n (%) 9/583 (2 %) -
CABG, n (%) 20/583 (3%) 41/241 (17%) <0.001
Conservative, n (%) 69/583 (12%) 96/236 (40%) <0.001
Death, n (%)                           71/574 (12%)                          47/236 (20%)              0.006
CAG = coronary angiography, PCI= percutanous coronary intervention, CABG= coronary artery
bypass grafting. 
At discharge, non-STEMI patients less frequently received clopidogrel, ACE-
inhibitors or statins than STEMI patients.  Nitrates and calcium channel blockers
were prescribed more often in the non-STEMI patients. Aspirin and beta blockers
were prescribed equally in both groups (Table 3). 
Table 3: Discharge medication
                                               STEMI                                      non-STEMI              P-value
Aspirin, n (%) 472/552 (86%) 187/221 (85%) 0.75
Beta blocker, n (%) 484/553 (88%) 188/221 (85%) 0.36
Clopidogrel, n (%) 381/553 (69%) 91/227 (40%) <0.001
Statines, n (%) 356/552 (65%) 126/221 (57%) 0.052
ACE-i, n (%) 300/553 (54%) 87/221 (39%) <0.001
Nitrate 67/447 (15%) 65/221 (29%) <0.001
Calcium channel blocker         16/446 (4%)                            40/221 (18%)              <0.001
ACE-i: angiotensin converting enzyme inhibitor.
Outcome
At 3 year follow up, mortality was 20% in the non-STEMI and 12% in the STEMI
patients, P =0.006 (Figure 1). Univariate predictors of mortality in the non-STEMI
patients were age, diabetes, previous myocardial infarction and not performing
coronary angiography (CAG) (Table 4). The excess mortality could not be
attributed to the higher CABG rate in the non-STEMI. Mortality rate was 3/41 (7%)
vs. 2/20 (10%), P =0.65, in the non-STEMI and STEMI patients who underwent
CABG. Are non-STEMI patients undertreated?                                                                      
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Figure 1: Mortality curves stratified according to MI category
Univariate predictors of mortality in the STEMI patients were age, diabetes,
previous myocardial infarction, hypertension, not smoking and not performing
CAG (Table 4).
Table 4: Univariate analysis; predictors of mortality 
           Non-STEMI       STEMI 
Variable                      OR        95% CI            P-value           OR        95% CI          P-value
Age 1.14 1.09-1.20 <0.001 1.10 1.08-1.14 <0.001
Female gender 0.85 0.43-1.68 0.64 0.58  0.33-1.02 0.06
Diabetes 4.64 2.21-10.15 <0.001 3.6 1.93-6.72 <0.001
Previous MI 4.42 2.12-9.21 <0.001 2.18 1.51-5.24 0.001
Hypertension 1.03 0.53-2.02 0.93 2.41 1.36-4.29 0.003
Smoking 0.58 0.26-1.30 0.19 0.39 0.21-0.74 0.004
No CAG                      19.43   8.90-42.4        <0.001             3.67     6.78-27.63      <0.001
MI= myocardial infarction
Cox proportional hazard Analysis
The following factors were included in the Cox-regression analysis: age, gender,
diabetes, previous MI, hypertension, smoking, non-STEMI (STEMI reference) and
not performing CAG. This analysis revealed that age, diabetes, previous MI and
not performing CAG were significantly associated with increased risk of mortality
(Table 5). 
Log rank P = 0.003
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Table 5: Hazard ratios of mortality of the significant factors in the multivariate model
Variable                                              HR                   95% CI                        P-value
Age 1.06 1.04-1.10 <0.001 
Female gender 1.20 0.76-1.90 0.43
Diabetes 2.12 1.34-3.35 0.001
Previous MI 1.64 1.04-2.60 0.03
Hypertension 1.35 0.95-2.75 0.15
Smoking 1.54 0.89-2.05 0.13
Non-STEMI* 1.07 0.88-2.65 0.76
No CAG                                              3.55                 2.12-5.93                    <0.001
MI= myocardial infarction, * STEMI is reference group
Discussion
This study identifies important differences in patient characteristics and
management among patients discharged with the diagnosis of non-STEMI versus
STEMI in a cohort of unselected patients. The higher mortality of patients with
non-STEMI was due to differences in baseline characteristics and treatment. 
The ratio of STEMI/non-STEMI is higher in our study as compared to other
studies [7]. The is due to the fact that, STEMI patients are consisted of those who
are admitted primarily to our hospital, referred patients and those diagnosed by
paramedics of the ambulance and transported directly to our centre for primary
PCI. While, non-STEMI patients consisted only those admitted directly to our
hospital.
Our results are in accordance with a previous study [7],
 showing that non-STEMI
patients have higher risk profiles and are treated less often with guideline
recommended medication. The lower mortality rate in our study may be due to
differences in treatment, rates of coronary angiography and revascularisation
therapy that were higher in our study. The prognosis after MI, for both non-STEMI
and STEMI in our study is worse as compared to two previous registries: the Euro
Heart Survey of Acute Coronary Syndromes (EHS-ACS) and the Global Registry
of Acute Coronary Events (GRACE) [8,9]. Possibly, in both GRACE
 and EHS-
ACS, some high-risk patients may have been excluded. For example, patients
dying within 24 h of admission
 were excluded from GRACE. 
Furthermore, compared to our study, many large scale randomized trials have
reported lower mortality at one year follow up after MI [10-14]. The reason for this
difference in outcome may due to low external validity of these trials due to
numerous inclusion and exclusion
 criteria in these trials. Therefore, their results
can not be reasonably applied to patients in routine clinical practice [15].Are non-STEMI patients undertreated?                                                                      
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Nevertheless, large scale clinical trials provide the most reliable data on the
effects of treatment. Results of registries are suggested to be more externally
valid than randomized trials because they include all patients and are performed
in a real world setting [16-17].                                                                                                              
Reasons for different outcomes 
The fact that non-STEMI patients were older, had higher risk profiles, were more
often treated conservatively and less frequently received guideline recommended
medication at discharge, might possibly explain the difference in mortality rate.
These results are in accordance with a previous study, showing that an early
invasive management strategy is not utilized in many high-risk patients [18]. An
invasive strategy appears to be reserved for patients without significant co-
morbidities and with a lower risk of in-hospital mortality.
 However, in patients older
than 75 years of age, a routine early invasive strategy may significantly improve
clinical outcomes [19]. Finally, the fact that circumflex artery occlusions are more
likely to present as non-STEMI than as STEMI might contribute to the worse
outcome in non-STEMI patients [20]. 
Challenges to improve outcome
The outcomes in patients with acute coronary syndromes have improved over
time. This was associated with the use of antiplatelet and antithrombotic therapies
and the increased utilization of revascularization [21]. However, despite these
improvements non-STEMI patients may have worse outcome [22]. Other factors
than patient characteristics and treatment strategy that may account for worse
outcome in non STEMI are the fact that identification of MI is often delayed due to
lack of definitive ECG abnormalities and timing of cardiac troponin elevation
[23,24]. In addition, almost half of patients with non-STEMI have other symptoms
than chest pain at presentation, which may contribute to delayed diagnosis [25].
The question remains how we can further improve the outcome of patients with
non-STEMI. This may be achieved by a multifactorial approach; first, identifying
high risk patients, which can be done through a good clinical evaluation of
medical history, physical examination, electrocardiogram (ECG) and cardiac
biomarkers e.g. myoglobin, cardiac troponin and CK-MB [26,27]. Second, using
the TIMI Risk Score, a simple clinical score that may be used by the clinician at
the bedside for risk assessment and therapeutic decision-making, and may
improve patient management [28,29]. Third, an early invasive strategy may
improve outcome. Several clinical trials have shown the beneficial effect of thisChapter 2.1
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strategy, and this may be even greater when combined with early initiation of
glycoprotein IIb/IIIa inhibitors [18,22,30-32]. Finally, recent  data from the
CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress
ADverse outcomes with Early implementation of the ACC/AHA guidelines)
demonstrated that guideline recommended medication is underused despite their
proven clinical benefit [33].Treating patients according to the current guidelines
[1,5] will improve prognosis after MI, as has been reported in recent studies [34-
36].  
Future trials
All the above mentioned trials have increased our knowledge with regard to how
we should treat high-risk patients with non-STEMI. However, very early
aggressive therapy in non-STEMI patients, as is performed in STEMI, remains a
field for further research. Additional studies are warranted to evaluate whether
immediate cardiac catheterization and reperfusion in high-risk non-STEMI
patients will further improve the outcome. 
Conclusions
This study shows important differences in baseline characteristics, treatment and
prognosis between non-STEMI and STEMI patients. A more invasive therapy and
guideline recommended treatment might further improve outcome after MI,
especially in the non-STEMI population.
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Abstract
Background: More than 10 years ago, survival benefit of primary percutaneous
coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) was
demonstrated in several randomised trials. Since then, primary PCI has been
implemented in routine daily practice and is in the guidelines the preferred
reperfusion therapy for patients with STEMI. However, results of randomised trials
may differ from those in daily practice, and the primary PCI procedure has
evolved. 
We aimed to assess time-dependent changes in baseline characteristics,
concomitant treatment and prognosis in patients with STEMI treated with primary
PCI. 
Methods and Results: Individual patient data from all 4732 patients admitted for
primary PCI for STEMI between 1994 and 2004 in our hospital were recorded.
Patient characteristics, concomitant treatment and one-year outcome were
evaluated. During the 11 years period, mean age and proportion of females were
increasing, whereas door to balloon time decreased. Stent implantation rates
increased from 2% to 84%. At discharge, prescription of aspirin, beta-blockers,
statins, and ADP receptor blockers increased significantly. From 1994 to 2004,
hospital stay shortened from 10.4 to 4.5 days P<0.001. Hospital and one-year
mortality decreased, from 6.7% to 1.4% and 9% to 4.9% (both P<0.001),
respectively.
Conclusions: Between 1994 and 2004, utilization of stents and recommended
pharmacotherapies increased remarkably. In-hospital stay and both hospital and
one-year mortality decreased significantly.                                                                                                                   Chapter 2.2
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Introduction
Both European and American guidelines state that primary percutaneous coronary
intervention (PCI), if possible, is the preferred therapeutic option in patients with ST-
elevation myocardial infarction (STEMI) [1,2]. Primary PCI is defined as intervention
of the infarct related vessel within 12 h after the onset of symptoms, without prior
thrombolytic therapy [3]. It was already performed in 1979 [4], but in 1993 the first
randomized clinical trials showed superior efficacy and safety of primary PCI over
thrombolysis [5-7]. Since then, primary PCI has been implemented in clinical daily
practice, and became available for a broad range of patients.
Primary PCI continues to evolve and it has changed most radically with adjunctive
therapy- glycoprotein IIb/IIIa inhibitors [8], thienopyridines [9]
 and reliance on stent
implantation [10-12]. Furthermore, extensive use of aspirin, statins, beta-blockers and
the common use of angiotensin-converting enzyme inhibitors (ACE-i), may further
reduce morbidity and mortality [13-15].
After publication of the first randomized trials in 1993, primary PCI was implemented
in daily practice in our hospital, and since 1994 all patients with STEMI were treated
with primary PCI. So, we have the opportunity to assess time dependent changes in
baseline characteristics, concomitant treatment, and prognosis in patients with
STEMI, admitted for primary PCI.
Aim
To assess time dependent progress in primary PCI for STEMI from 1994 through
2004.
Patients and Methods
Population 
From January 1994 to December 2004, individual patient data from all eligible
patients with admission diagnosis of STEMI admitted for primary PCI at the Isala
klinieken (Zwolle, the Netherlands) were prospectively recorded. To avoid double
inclusion of patients, only the first recorded admission for STEMI during the study
period was used. Patients were diagnosed with STEMI if they had chest pain of >
30 minutes' duration and ECG changes with ST segment elevation > 2 mm in at
least 2 precordial leads and > 1 mm in the limb leads. Before the primary PCI
procedure all the patients received intravenous aspirin and heparin [16].Primary PCI for STEMI: Zwolle experience                                                               
36
Data collection and follow-up
We collected the following variables from the patient files:
 age, gender, history of
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction
and discharge medication. Data were grouped according to the calendar year of
patient’s hospital admission. Follow-up information was obtained from the
patient's general physician or by direct telephone interview with the patient. Data
were grouped according to admission year and started from 01 January to 31
December. Study approval was obtained from the medical ethic committee of our
hospital.
Statistical Analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation and categorical data as percentage,
unless otherwise denoted. The analysis of variance and the Mantel-Haenszel chi-
square test were appropriately used for continuous and categorical variables
respectively. Binary logistic analysis was performed to evaluate the risk of
hospital mortality. To assess time-related changes in prognosis, patients were
categorized to the admission year, with 1994 as the reference year. Significant
variables analyzed are reported with their respective odd ratios and 95%
confidence intervals. Cox proportional-hazards regression models were used to
estimate hazard ratios of clinical variables with regard to major adverse cardiac
events (death, reinfarction or re PCI) at one year. For all analyses, statistical
significance was assumed when the two-tailed probability value was < 0.05.
Hospital stay was analysed only in non-referred patients.
Results 
Baseline characteristics 
From 1994 through 2004, a total of 4732 patients with STEMI were admitted for
primary PCI at our hospital. The annual number of the patients increased from
178 in 1994 to 633 in 2004 (Figure 1). Mean age of the patients was 61 (19-95)
years, 24% were female, 11% had a history of previous myocardial infarction and
11% diabetes mellitus. A total of 2045 of the patients (43.2%) were referred from
non-PCI performing referring centres. From 1994 to 2004, mean age of the patients
increased from 59.7 to 62.4 years and rate of patients ≥ 75 years old increased
significantly (Figure 2).                                                                                                                   Chapter 2.2
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Figure 1: Annual number of patients admitted for primary PCI
Figure 2: Percentage of patients with age ≥75 year
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The proportion of females rose from 20% to 27%. There was a reduction in the
rate of patients with previous myocardial infarction, anterior myocardial infarct
location and Killip class>2, but an increase in the rates of hypertension and
hypercholesterolemia. Ischemic time and patient delay remained unchanged,
while door to balloon time decreased significantly (Table 1).  
Treatment
From the 4732 patients, 4300 were treated with primary PCI (90.9%), 170
patients (3.6%) underwent coronary artery bypass graft surgery and 262 patients
(5.5%) were treated conservatively (Table 2). Among the patients underwent
primary PCI, there was a sharp rise in stent implantation, from less than 2% to
84% (Figure 3). During the study interval, post primary PCI Thrombolysis in
Myocardial Infarction (TIMI) 3 flow grade was achieved more frequently (Table 2). 
Table 2: treatment
Variables (%) 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 P-value
No.of patients 178 251 299 328 427 410 470 446 665 625 633
Treatment 0.73
PCI 91.6 90.8 90 88.1 90.9 94.4 91.3 91 89.6 90.1 91.8
CABG 3.4 3.6 3.3 4.6 4.4 2.9 3.4 3.4 4.1 4 2.7
Conservative 2.8 4.4 5.7 6.8 3.1 2.2 2.3 4.86 4.3 4.1 3.4
Stent  1.9 11.5 30.9 49.8 54.5 55.1 60.6 60.6 76.8 80.0 84.1 <0.001
Post-PCI TIMI 3 86.1 85.6 88.4 80.9 85.3 85.5 88.8 88.6 90.3 93.9 91.2 <0.001
Medication
Aspirin 78.8 81.3 84.7 83.6 86.6 90.3 88.1 88.3 95.4 93.8 93.8 <0.001
B-Blocker 72.2 71.7 73.1 81.7 77.4 84.6 82.7 87.4 87.9 88.2 92.5 <0.001
Calcium chan bl 17.2 10.5 9.3 7.6 3.9 4 3.6 3.4 3.5 5 3.5 <0.001
ADP inhibitor 0 0.5 25.4 9.8 28.2 28.5 53.1 67.8 85.3 87.8 89 <0.001
ACE-i 52.6 48.7 51.1 55.7 45.3 51.6 50.3 53.6 54.4 54.1 56.8 0.052
PCI: percutaneous coronary intervention    CABG: coronary artery bypass grafting, B-blocker: beta
blocker, Calcium chan bl: calcium channel clocker, ADP inhibitor: adenosine diphpsphate inhibitor,
ACE-i: angiotension converting inhibitors
Discharge prescriptions for cardiac medications also changed over time.
Prescriptions of aspirin, beta-blockers, statins, and ADP receptor blockers
increased significantly. There was a slight increase in the prescription of ACE-i
between 1994 and 2004, from 52.6% to 56.7%, p=0.052. In patients with anterior
and non-anterior myocardial infarction ACE-i prescription increased from 66.7% to
72.1%, p=0.14 respectively 30.5% to 42.4%, p=0.003. Prescription of calcium
channel blockers decreased significantly (Table 2; Figure 3). Primary PCI for STEMI: Zwolle experience
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Figure 3: Pharmacotherapy 
Outcome 
In hospital 
Duration of hospital stay in survivors decreased from 10.4 to 4.5 days, p<0.001,
(Figure 4). Rates of re-infarction decreased significantly, from 1.7% to 0.6%.
Hospital mortality declined from 1994 through 2004 from 6.1% to less than 1.5%
(Figure 5). In referred patients this decreased from 7% to 1.1%.
The cumulative incidence of major adverse cardiovascular events
  (death, re-
infarction or re-PCI) declined from 1994 through 2004 from 16.9% to 6.6%,
p=0.001. The unadjusted and adjusted (age, gender, previous MI, hypertension,
hypercholesterolemia, anterior myocardial infarct location and Killip class) odds
ratio of mortality from 1994 through 2004 was 0.85/year (95%CI: 0.81-0.90) and
0.85/year (0.80-0.91), respectively. Thus there was a mean decrease of 15% in
hospital mortality each year. Chapter 2.2
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Figure 4: Hospital stay in non-referred and referred patients 
Figure 5: Hospital mortality
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One- year
During the study interval, mortality and reinfarction rates decreased significantly,
from 9% to 4.9%; p=0.002 and from 4.5% to 3.5%; p< 0.001, respectively. The
cumulative incidence of major adverse cardiovascular events
 (death, re-infarction
or re-PCI) decreased significantly between 1994 and 2004 (Figure 6). 
Figure 6: Major adverse outcome at one year
The unadjusted and adjusted (age, gender, previous MI, hypertension,
hypercholesterolemia, anterior myocardial infarct location and Killip class) odds
ratio of major adverse cardiac events from 1994 through 2004 was 0.93/year
(95%CI: 0.90-0.97) and 0.93/year (0.89-0.96), respectively.
Discussion 
This study presents 11 years of experience with primary percutaneous coronary
intervention for ST-elevation myocardial infarction. Rates of primary PCI and stent
implantation have increased considerably. Utilization of aspirin, beta-blockers,
statins and ADP receptor blockers increased also significantly. Despite increasing
age of the patients, there was a decrease in hospital stay and hospital mortality or
re-infarction. At one-year follow up there was also a decline in one-year mortality
and a decline in the combined composite of death, reinfarction and/or re-PCI.
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Primary percutaneous coronary intervention (PCI)
The superiority of primary PCI over thrombolysis has been well studied [5-
7,17,18]. Both European and American guidelines state that primary PCI is the
preferred therapeutic option in patents with STEMI admitted within 90 minutes
after diagnosis [1,2]. Because of the superior efficacy and safety of primary PCI
over thrombolysis, primary PCI has become routine daily clinical practice in our
center. Thrombolysis is no longer used in our hospital after 1994. Since then, all
eligible STEMI patients had immediate coronary angiography for revascularization
therapy. 
In the current study, the decline in hospital mortality from 1994 through 2004 may,
at least partially, due to the high volume in our centre. Several studies have
shown the relation between
 the volume of procedures and the outcome [19-21].
 
The use of stent implantation has increased from 2% to over 80% in our study.
Several randomized clinical trials have showed the association between stent use
in combination with primary angioplasty and outcome [10-12] although results
may be less clear [22]. 
Improved pharmacotherapy
The impact of pharmacotherapies on outcome after myocardial infarction has
been well studied. Medications that improve the outcome are aspirin, beta-
blockers, ACE-i, statins and ADP receptor blockers [9,13-15,23] whereas calcium
channel blockers seem to have deleterious effects [24]. Figure 3 shows that we
have incorporated these findings into daily practice. These trends are consistent
with other studies [25,25] showing increased prescription of guideline
recommended pharmacotherapies on discharge. 
 Improved outcome 
A significant decline in hospital stay and improved outcome was found. Results of
primary PCI changed only little (TIMI 3 flow post PCI increased from 86% to 91%)
and the major part of this favourable trend may be due to increased use of
pharmacotherapies after primary PCI. Furthermore, the lower incidence of
reinfarction can also partially explain the benefits in mortality observed in these
patients [27,28].
During the study period there were several changes in the baseline
characteristics. Prevalence of previous myocardial infarction, anterior myocardial
infarction or Killip class>2 decreased, whereas there was a significant increase of
the mean age, female proportion and particularly of patients ≥ 75 years old. This
reflects the change of our policy, nowadays accepting all (referred) patients withPrimary PCI for STEMI: Zwolle experience
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STEMI for primary PCI. After adjusting for these variables, however, our data
shows still improvement in both short-and long term outcome. These results are
consistent with recent data from the Euro Heart Survey, that showed an
improvement in both in-hospital and 30-day outcome after acute coronary
syndrome between 2000 and 2004 [25]. In addition, recently data from the
Register of Information and Knowledge about Swedish Heart Intensive Care
Admissions (RIKS-HIA) also showed improved outcome with primary PCI
between 1999 and 2004.
29 
 
Future directions
In this study we show progress in primary PCI and concomitant medical treatment
for STEMI. Nevertheless, there are several other factors that in combination with
primary PCI may further improve the outcome of patients with STEMI. Among
these factors are proximal or distal protection devices to prevent distal
embolization, stem cell therapy in patients with anterior myocardial infarction and
implantable cardiac defibrillators in high-risk patients. Pre-hospital diagnosis and
therapy initiation in the ambulance before transportation and the effect of newer
anti-thrombotic agents e.g. bivaliridin are also a field of interest. Currently, there
are additional trials going on to address these issues. 
Limitations
The patient population included in this study are all consecutive patients who
were included in the prospective registry from 1994 through 2004. Although we
tried to register all patients with STEMI, it however, is not possible to include all
patients e.g. STEMI patients that are not referred because of atypical chest pain
or presented too late. 
The treatment strategy and outcome may differ in those not enrolled in this
registry. We had no data on the use of glycoprotein IIb/IIIa inhibitors. The use of
these agents in patients with STEMI appeared to improve coronary patency with
favourable trends for clinical outcome [8]. Another limitation is that we only have
data on all cause-mortality and not on cause specific death.  
Conclusions
These data show the 11 years experience of primary PCI in a high volume center.
It shows a decrease in hospital stay, increased utilization of effective
pharmacotherapies and improvements in clinical outcome despite increasing ageChapter 2.2
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of the patients. This analysis confirms the previous randomised trials,
demonstrating that primary PCI for STEMI is safe and highly effective in routine
daily practice. Primary PCI for STEMI: Zwolle experience
46
References
1-  Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D,
Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A,
Verheugt FW, Wijns W; Task Force on the Management of Acute Myocardial
Infarction of the European Society of Cardiology. Management of acute myocardial
infarction in patients presenting with ST-segment elevation. The Task Force on the
Management of Acute Myocardial Infarction of the European Society of Cardiology.
Eur Heart J. 2003; 24:28-66.
2-  Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS,
Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan
MA, Smith SC Jr; American College of Cardiology; American Heart Association;
Canadian Cardiovascular Society. ACC/AHA guidelines for the management of
patients with ST-elevation myocardial infarction--executive summary. A report of the
American College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Writing Committee to revise the 1999 guidelines for the management of
patients with acute myocardial infarction). J Am Coll Cardiol. 2004; 44:671-719.
3-  Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E,
Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for
Percutaneous Coronary Interventions of the European Society of Cardiology.
Guidelines for percutaneous coronary interventions. The Task Force for
Percutaneous Coronary Interventions of the European Society of Cardiology. Eur
Heart J. 2005; 26:804-847.
4-  Rentrop P, Blanke H, Wiegand V, Karsch KR. Recanalization by catheter of the
occluded artery after acute myocardial infarction (transluminal recanalization
(author's transl)] Dtsch Med Wochenschr. 1979 ;104:1401-1405. 
5-  Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JH, Suryapranata H. A
comparison of immediate coronary angioplasty with intravenous streptokinase in
acute myocardial infarction. N Engl J Med. 1993; 328:680-684.
6-  Grines CL, Browne KF, Marco J Rothbaum D, Stone GW, O'Keefe J, Overlie P,
Donohue B, Chelliah N, Timmis GC, for the Primary Angioplasty in Myocardial
Infarction Study Group. A comparison of immediate angioplasty with thrombolytic
therapy for acute myocardial infarction. N Engl J Med. 1993; 328: 673–679.
7-  Gibbons RJ, Holmes DR, Reeder GS, Bailey KR, Hopfenspirger MR, Gersh BJ.
Immediate angioplasty compared with the administration of a thrombolytic agent
followed by conservative treatment for myocardial infarction. The Mayo Coronary
Care Unit and Catheterization Laboratory Groups. N Engl J Med. 1993; 328:685-691.
8-  Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late
administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary
intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
JAMA. 2004; 292:362-366.
9-  Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux
P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive
Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28
Investigators. Effect of clopidogrel pretreatment before percutaneous coronary
intervention in patients with ST-elevation myocardial infarction treated with
fibrinolytics: the PCI-CLARITY study. JAMA. 2005; 294:1224-32.Chapter 2.2
47
10- Ahmad T, Webb JG, Carere RR, Dodek A. Coronary stenting for acute myocardial
infarction. Am J Cardiol. 1995; 76:77–80. 
11- Antoniucci A, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical
trial comparing primary stenting of the infarct-related artery with optimal primary
angioplasty for acute myocardial infarction: results from the Florence Randomized
Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol.
1998; 31:1234-1239. 
12- Suryapranata H, van ’t Hof AWJ, Hoorntje JCA, de Boer MJ, Zijlstra F. Randomized
comparison of coronary stenting with balloon angioplasty in selected patients with
acute myocardial infarction. Circulation. 1998; 97:2502-2505. 
13- Collins R, Peto R, Baigent C, Sleight P. Aspirin, heparin, and fibrinolytic therapy in
suspected acute myocardial infarction. N Engl J Med. 1997; 336:847-860.
14- Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR,
Geltman EM, Goldman S, Flaker GC, on behalf of the SAVE Investigators. Effect of
captopril on mortality andmorbidity in patients with left ventricular dysfunction after
myocardial infarction. Results of the Survival and Ventricular Enlargement Trial. N
Engl J Med 1992; 327:669–677.
15- Hennekens C, Albert C, Godfried SL, Gazizno JM, Buring JE. Adjunctive drug
therapy of acute myocardial infarctionevidence from clinical trials. N Engl J Med.
1996; 335:1660-1667. 
16- Liem A, Zijlstra F, Ottervanger JP, Hoorntje JCA, Suryapranata H, de Boer MJ,
Verheugt FW. High dose heparin as pretreatment for primary angioplasty in acute
myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am
Coll Cardiol. 2000; 35:600-604
17- De Boer MJ, Ottervanger JP, van 't Hof AWJ, Hoorntje JCA, Suryapranata H, Zijlstra
F; Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients
with acute myocardial infarction: a randomized comparison of primary angioplasty
and thrombolytic therapy. J Am Coll Cardiol. 2002; 39:1723-1728.
18- Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative review of 23
randomised trials. Lancet. 2003; 361:13-20.
19- Canto JG, Every NR, Magid DJ, Rogers WJ, Malmgren JA, Frederick PD, French
WJ, Tiefenbrunn AJ, Misra VK, Kiefe CI, Barron HV. The volume of primary
angioplasty procedures and survival after acute myocardial infarction. National
Registry of Myocardial Infarction 2 Investigators. N Engl J Med. 2000;342:1573-
1580.
20- Thiemann DR, Coresh J, Oetgen WJ, Powe NR. The association between hospital
volume and survival after acute myocardial infarction in elderly patients. N Engl J
Med. 1999; 340:1640-1648. 
21- Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Do "America's Best
Hospitals" perform better for acute myocardial infarction? N Engl J Med. 1999;
340:286-292.
22- De Luca G, Suryapranata H, van 't Hof AWJ, Ottervanger JP, Hoorntje JCA,
Dambrink JHE, Gosselink ATM, de Boer MJ. Impact of routine stenting on
myocardial perfusion and the extent of myocardial necrosis in patients undergoingPrimary PCI for STEMI: Zwolle experience
48
primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J.
2006 ;151:1296.e1-6.
23- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol
lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S). Lancet. 1994; 344:1383-1389.
24- Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in
patients with coronary heart disease. Circulation. 1995; 92:1326–1331.
25- Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai
D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S. The second Euro
Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome
of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J.
2006; 27:2285-2293. 
26- Dauerman HL, Lessard D, Yarzebski J, Furman MI, Gore JM, Goldberg RJ. Ten-year
trends in the incidence, treatment, and outcome of Q-wave myocardial infarction. Am
J Cardiol. 2000; 86:730-735.
27- Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, Mattos L, Lansky AJ,
O'Neill WW, Grines CL. Normal flow (TIMI-3) before mechanical reperfusion therapy
is an independent determinant of survival in acute myocardial infarction: analysis
from the primary angioplasty in myocardial infarction trials. Circulation. 2001;
104;636-641. 
28- De Luca G, Ernst N, Zijlstra F, van 't Hof AWJ, Hoorntje JCA, Dambrink JHE,
Gosselink ATM, de Boer MJ, Suryapranata H. Preprocedural TIMI flow and mortality
in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll
Cardiol. 2004;43:1363-1367. 
29- Stenestrand U, Lindback J, Wallentin L; RIKS-HIA Registry. Long-term outcome of
primary percutaneous coronary intervention vs prehospital and in-hospital
thrombolysis for patients with ST-elevation myocardial infarction. JAMA. 2006;
296:1749-175.
 Chapter 2.3
49
Chapter 2.3
Feasibility and Benefit of Pre-Hospital Diagnosis, Triage and
Therapy by Paramedics only in Patients who are Candidates for
Primary Angioplasty for Acute Myocardial Infarction
Arnoud WJ van ’t Hof, Saman Rasoul, Henri van de Wetering, Nicolette Ernst,
Harry Suryapranata, Jan CA Hoorntje, Jan-Henk E Dambrink, Marcel
Gosselink, Felix Zijlstra, Jan Paul Ottervanger, Menko-Jan de Boer, on behalf
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Abstract
Background
Despite data showing that time to treatment is very important in ST elevation
myocardial infarct patients, unacceptable long delays to reperfusion remain
present in daily life practice. We sought to evaluate the feasibility and effect of
improving logistics by early infarct diagnosis in the ambulance and immediate
triage to a PCI center performed by paramedics only without interference of a
physician.
Methods
In the On-TIME (Ongoing Tirofiban In Myocardial infarction Evaluation) study, 209
patients were included after pre-hospital infarct diagnosis and triage in the
ambulance (Ambulance group, N=209). Infarct diagnosis was made by highly
trained paramedics with the help of a computerized ECG algorithm. The accuracy
of diagnosis, time to treatment, left ventricular function and clinical outcome were
compared with the patients who were diagnosed and triaged at a referral non-PCI
center (Referred group, N=258). Left ventricular function was assessed before
discharge using a nuclear technique. 
Results
Acute myocardial infarction was accurately diagnosed in 95% of patients in the
ambulance group as compared to 99% in the referred group (p=0.01). The
percentage of patients in whom pharmacologic pre-treatment (heparin, aspirin,
tirofiban or placebo) was initiated in the ambulance within 90 minutes after the
onset of symptoms was 59 % in the ambulance group vs. 43 % in the referred
group (p<0.01). A left ventricular ejection fraction (LVEF) of less than 40% was
present in 25 % in the ambulance group, as compared to 38 % in the referred
group (p=0.013). After multivariate analysis, ambulance triage was independently
associated with a LVEF > 40% and a favorable long term clinical outcome.
Conclusions
Early, pre-hospital infarct diagnosis, triage and therapy in the ambulance with
direct transportation to the nearest PCI center, performed by trained paramedics
only is feasible in 95% of patients. Ambulance triage resulted in earlier diagnosis
and initiation of therapy and was independently associated with a better left
ventricular function and clinical outcome, as compared to triage and
transportation from a referral non-PCI center.Chapter 2.3
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Introduction
Primary coronary angioplasty has been shown to be a very effective reperfusion
modality in patients with ST elevation myocardial infarction [1,2], even when
additional transport is necessary to a PCI center [3]. However, time to reperfusion
is often considerably longer when the data from registries are reported instead of
the data from randomized trials. In a large registry in the USA, only 5% of patients
had a door to balloon time less than 60 minutes [4]. Although door to balloon
times decreased from 90 to 70 minutes in the most recent Euro Heart Survey
analysis on acute coronary syndromes [5], many patients still have unacceptable
long times to treatment.   Some of the delay might be prevented by pre-hospital
infarct diagnosis and triage, selecting patients who are candidates for primary
angioplasty who can immediately be transported to a PCI center. However, it is
unclear whether this can be reliably performed by paramedics without
interference of a physician.
This study evaluates the feasibility and benefit of pre-hospital infarct diagnosis
and triage in the ambulance by paramedics only and compares outcome with
triage at a referral non-PCI center. 
Patients and Methods
The design, in- and exclusion criteria and main findings of the On-TIME (Ongoing
Tirofiban In Myocardial infarction Evaluation) study have been described
previously [6]. In this study, 209 patients were included after pre-hospital infarct
diagnosis and triage in the ambulance (Ambulance group, N=209). The accuracy
of diagnosis, time to treatment, the quality of reperfusion, left ventricular function
and clinical outcome was compared with the patients who were diagnosed and
triaged at a referral non-PCI center (Referred group, N=258). The presence of an
ambulance equipped with 12-lead ECG diagnostic facilities determined whether a
patient was transported to a non-PCI center first or immediately referred to the
PCI center.
Emergency transportation was performed after a telephone call, done either by
the ambulance driver (ambulance group) or the referring physician (referred
group), with the aim to prepare the arrival of the patient directly at the
catheterization laboratory. Recruitment and randomization in the ambulance was
initiated only after a period of training in pre-hospital infarct diagnosis and care for
at least 6 months. All paramedics had at least 2 years of training at a (cardiac)
intensive care unit and worked strictly according to board certified protocols.
Computer diagnosis in the ambulance was made based upon a fixed algorithm,
which has been described previously [7,8]. Before transportation all patientsShift towards earlier diagnosis and treatment
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received 500 mg of aspirin and 5.000 IU of unfractionated heparin intravenously
and study medication (tirofiban or placebo). Post PCI, all patients were treated
with clopidogrel (300 mg loading dose followed by 75 mg daily for one month),
aspirin, beta blockade, statin, and ACE inhibition.
Time from symptom onset to diagnosis was defined as the time from the onset of
symptoms to the time of the diagnostic ECG, either made in the ambulance or at
the non-PCI center. Total ischemic time was defined as the time from symptom-
onset to first balloon inflation.
All angiographic and electrocardiographic parameters were analyzed by an
independent core-lab (Diagram BV, Zwolle, the Netherlands) and scored by
observers who were unaware of randomization and outcome data. A correct
infarct diagnosis was defined as prolonged chest pain with typical evolutionary
electrocardiographic changes, coupled with an unstable coronary lesion on the
angiogram and a rise in CK of more than 3 times the upper limit of normal.
Prevented myocardial infarction was defined as a correct infarct diagnosis without
a rise in CK of more than 3 times the upper limit of normal. A false positive infarct
diagnosis was made in those patients who did not meet the criteria for a correct or
prevented myocardial infarction. Left ventricular ejection fraction (LVEF) was
assessed in the patients recruited in the Zwolle area only and was measured with
a radionuclide technique before discharge, as previously described (1). The data
on LVEF were gathered by a specialist in nuclear medicine, who was blinded to
the clinical data.   Clinical outcome, being the incidence of death or recurrent
myocardial infarction, was assessed at 1 year follow-up.
Statistical Analysis
Statistical analysis was performed with the SPSS 10.0 statistical package. All
non-continuous angiographic variables were analysed using the Chi-square test
or Fisher exact test. Continuous variables were analysed using analysis of
variance or Mann Whitney test. The continuous variables time from symptom
onset to diagnosis and total ischemic time were dichotomized, based upon the
median value (94 minutes and 188 minutes respectively). Key outcome
parameters were the percentage of patients with a correct infarct diagnosis, left
ventricular ejection fraction before discharge and the 1 year incidence of death or
recurrent myocardial infarction. Risk stratification was based upon the previously
described TIMI risk criteria (9). To assess independent predictors of left
ventricular function and clinical outcome, multivariate analysis was performed,
using stepwise logistic regression. All parameters which were significantly
different between the groups (gender and distance to the PCI center) and all
baseline characteristics associated with left ventricular function or clinicalChapter 2.3
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outcome with a p-value of 0.10 or less were entered into the model. The cutoff
value of 40% for determination of a poor left ventricular function was based upon
a value lower than the 25% percentile (38%).
Results
A correct infarct diagnosis was present in 95% of patients triaged by ambulance
personnel as compared to 99% triaged at a referral center (p=0.01). The 14
patients with a false positive infarct diagnosis either had severe aortic stenosis
(3), left ventricular hypertrophy with strain (1), previous myocardial infarction with
persistent ST elevation (2), atrial fibrillation with early repolarization (2),
pericarditis (2), gastro-intestinal disease (2) or other (2). 
Baseline characteristics of the ambulance and the referred group are described in
Table 1 and were not significantly different, except for gender and distance to the
PCI center (45 vs 24 km, p<0.001). The percentage of patients who were
diagnosed within 90 minutes or underwent balloon inflation within 3 hours after
the onset of symptoms was also different and significantly higher in patients after
triage in the ambulance (Table 1). Both initial perfusion of the infarct related
vessel and final myocardial perfusion as assessed by the myocardial blush grade
was better in the patients triaged in the ambulance (Table 1). 
Prevented myocardial infarction was present in 15% in the ambulance group and
in 10% in the referred group (p=0.08). Left ventricular ejection fraction was
measured before discharge in 318 of the 426 (75%) patients with a confirmed
diagnosis of acute myocardial infarction, recruited in the Zwolle area. The LVEF
was 46% ± 10 in the ambulance group as compared to 44% ± 11 in the referred
group (p=0.17). A left ventricular ejection fraction of less than 40% was present in
25% in the ambulance group, as compared to 38% in the referred group
(p=0.013).Shift towards earlier diagnosis and treatment
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Table 1: Baseline, Electrocardiographic and Angiographic Characteristics 
Referred Ambu P-value
                                                            (N=258)                        (N=209)                                    
Baseline
Age ( yrs ± SD) 62 ± 11 61 ± 11 0.88
Male gender 77% 85% 0.03
Diabetes 9% 13% 0.17
Hypertension 29% 26% 0.37
Smoking
* 66% 64% 0.68
Anterior MI 46% 46% 0.90
Previous MI 10% 7% 0.24
Previous CABG  1.6% 2.4% 0.52
Previous PCI 4.3% 5.8% 0.46
Killip class > 1
† 16% 19% 0.39
TIMI risk score > 3
‡ 42% 46% 0.38
SO to diagnosis < 90 min 43% 59% 0.001
Ischemic time < 3 hrs 29% 52% 0.001
Electrocardiographic
Cum. ST elevation (mm) 10 ± 7 11 ± 8 0.24
Cum. ST deviation (mm) 15 ± 9 15 ± 9 0.81
Angiographic
Single vessel disease 41% 49% 0.11
Pre PCI 
TIMI 2,3 35% 44% 0.04
Post PCI
TIMI 3 91% 91% 0.97
            MBG 3                                    47%                             59%                             0.02     
*current or previous smoking. 
†defined as systolic blood pressure < 100 mm Hg or heart rate > 100
/min. 
‡TIMI risk score as described by Morrow et al (9). 
CABG = coronary artery bypass grafting. MBG = myocardial blush grade as previously defined (18).
PCI = percutaneous coronary intervention. SO = symptom onset. 
Discharge medication
Discharge medications are shown in Table 2. On discharge the vast majority of
patients received aspirin, beta-blocker, statin and clopidogrel.Chapter 2.3
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Table 2: Medication at 30 days follow-up
Referred Ambu P-value
                                                            (N=239)                        (N=202)                                       
Aspirin 93% 89% 0.17
Oral anticoagulation 10% 10% 0.90
Beta blocker 89% 84% 0.13
Calcium channel blockers 6% 4% 0.24
Nitrates 17% 15% 0.51
ACE inhibitor 53% 57% 0.43
Statin 88% 85% 0.33
Clopidogrel*                                        81%                             76%                             0.19              
* Use at discharge
Univariate and Multivariate analysis
Left ventricular function
Univariate predictors of a poor left ventricular function were male gender, anterior
infarct location, the presence of diabetes, an initial heart rate > 100 beats/min, a
TIMI risk score above 2 and non-ambulance triage. After multivariate analysis,
only male gender, anterior infarct location and non-ambulance triage were
independently associated with a poor left ventricular function (Table 3).
Clinical outcome
At 30 day follow-up, 1.0% of patients with a correct diagnosis of acute myocardial
infarction had died in the ambulance group as compared to 3.2% in the referred
patients (p=0.2). At one year follow-up, total mortality and the combined incidence
of death or recurrent myocardial infarction was significantly lower in the
ambulance group (2.1% vs. 6.0%, p=0.04 and 3.6% vs 10.5%, p=0.006
respectively). After multivariate analysis, ambulance triage remained an
independent predictor of survival free from death or myocardial infarction at one
year follow-up (Table 3).Shift towards earlier diagnosis and treatment
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Table 3: Predictors of left ventricular function and clinical outcome
Variables                                                                      OR                    95% CI                   P-value
Left Ventricular Ejection Fraction < 40%
Univariate
Male gender 1.8 0.9 - 3.6 0.08
Diabetes 2.1 1.0 – 4.4 0.04
Anterior infarct location 6.3 3.7 – 10.8 <0.01
Heart rate > 100 / min 3.1 1.0 – 9.3 0.03
TIMI risk score > 2 5.9 3.2 – 10.8 <0.01
Distance < 41 km 0.8 0.5 – 1.4 0.54
Ambulance triage 0.5 0.3 – 0.8 0.01
Single vessel disease 1.0 0.7 – 1.8 0.71
Multivariate
Male gender 2.6 1.2 - 5.5 0.02
Anterior infarct location 3.7 1.6 – 8.9 <0.01
Ambulance triage 0.4 0.2 – 0.8 0.01
Death or recurrent myocardial infarction at 1 year follow-up
Univariate
Age (per year) 1.05 1.0 – 1.1 0.02
Male Gender 1.8 0.6 – 5.2 0.29
Hypertension 2.7 1.3 – 5.5 0.01
Anterior infarct location 1.9 0.9 – 3.2 0.08
Heart rate > 100 / min 3.0 1.2 – 7.9 0.03
TIMI risk score > 2 2.2 1.1 – 4.5 0.03
Single vessel disease 0.4 0.2 – 0.9 0.03
Distance < 41 km 0.7 0.3 – 1.4 0.29
Ambulance triage 0.3 0.1 – 0.7 0.01
Multivariate
Ambulance triage 0.3 0.1 – 0.9 0.03
Hypertension 2.5 1.1 – 5.5 0.03
Single Vessel disease 0.4 0.2 – 1.0 0.05
Anterior infarct location                                              2.3                   1.0 – 5.3                       0.05
Discussion
This study showed that correct infarct diagnosis, triage and therapy can be
performed by highly trained paramedics only, without interference of a physician,
in 95% of patients. Furthermore, it shows that ambulance triage is an independent
predictor of a left ventricular ejection fraction of more than 40 % and a favorable
clinical outcome, as compared to triage at a referral non-PCI center. The
mechanism of the beneficial effect seems to be the combination of earlierChapter 2.3
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diagnosis, earlier initiation of pharmacologic pre-treatment and a better initial and
final myocardial perfusion. It showed that further streamlining of logistics, in which
an unnecessary visit of a non-PCI center is prevented, saves time and is
associated with a better left ventricular function and clinical outcome. 
Pre-Hospital Care
The most recent version of the ACC/AHA guidelines for the treatment of patients
with ST elevation acute myocardial infarction state that primary angioplasty is the
preferred reperfusion strategy if it can be performed within 90 minutes after first
patient contact [10]. However, it was recently shown that only 5% of transferred
patients in the USA have a door-to balloon time of less than 90 minutes (4). Also
in Europe, every day door-to-balloon times are considerably longer than those
reported in randomized controlled trials [11]. This long delay prevents further
development of primary angioplasty programs, and is often stated as an excuse
for treating the patients with thrombolysis or a combined pharmaco-invasive
strategy, which so far, has not been supported by evidence from randomized
controlled trials. Many obstacles have been associated with the lack of
development of a pre-hospital diagnosis and care program of patients with an
acute myocardial infarction. The fear of a false positive infarct identification when
diagnosis is made without interference of a physician is one of them. This study
shows that the combination of trained paramedics together with a validated
computerized ECG algorhythm results in a correct diagnosis in 95% of cases. 
Mechanism of benefit
It is unlikely that the reduced total ischemic time alone may sufficiently explain the
beneficial effect on left ventricular function. The moment of time saving is
important: saving 30 minutes in the very early phase of myocardial infarction is
expected to result in a larger benefit as compared to a saving of 30 minutes later
on, the so called ‘Golden Hour’ of reperfusion therapy [12,13]. The majority of
patients triaged in the ambulance were diagnosed within 90 minutes and treated
within 180 minutes after the onset of symptoms. This very early diagnosis and
therapy is probably related to the better myocardial blush grade after PCI in this
group [14]. In addition, a pre-hospital diagnosis gives the opportunity for early
initiation of anti-thrombotic and anti-platelet pre-treatment during transportation.
Agents like aspirin, heparin and glycoprotein 2b/3a blockers have shown to
improve initial patency of the infarct related vessel [15,16]. The very early
initiation of these agents in the ambulance group might explain the higher initial
patency rate in this group, resulting in a higher rate of prevented myocardial
infarction and might contribute to the better left ventricular function and clinical
outcome of these patients. This study confirms previous findings from our group,Shift towards earlier diagnosis and treatment
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which showed that extra transportation delay is associated with a worsening of
the left ventricular ejection fraction [17]. The difference in outcome cannot be
explained by a difference in medication after discharge as shown in Table 2.
Limitations
This study is a post-hoc analysis of patients recruited in the On-TIME trial and not
a randomized comparison between pre-hospital triage in the ambulance versus
triage at the referral center, however, randomization would be unethical, as this
would deliberately prolong time to treatment in one arm. The presence of an
ambulance equipped with 12-lead ECG diagnostic facilities determined whether a
patient was transported to a non-PCI center first or immediately referred to the
PCI center. In- and exclusion criteria were the same for both study groups.
However, multivariate analysis might correct differences in baseline
characteristics between the groups, although this statistical correction might not
overcome the problem of undetectable confounders and is less reliable in a
relatively small sized trial with a low incidence of the outcome parameter of
interest. Left ventricular ejection fraction was routinely performed at discharge in
the patients recruited in the Zwolle area only (pre-specified LVEF substudy).
Patient characteristics of these Zwolle patients however did not differ significantly
from the patients recruited at other PCI centers.
Conclusion
Pre-hospital infarct diagnosis, triage and therapy in the ambulance is feasible
without physician interference when performed by highly trained paramedics
using validated computerized ECG software in 95% of patients. In addition, it was
found that ambulance triage was an independent predictor of a left ventricular
function of more than 40% and was independently associated with a favourable
clinical outcome. Therefore, all efforts should be made to implement pre-hospital
infarct diagnosis, triage, and therapy in the care of patients with an acute
myocardial infarction, and to further improve cooperation with ambulance
personnel in this regard.Chapter 2.3
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Abstract 
Aim
To compare dual versus triple antiplatelet pre-treatment in patients with non ST
elevation acute coronary syndrome (NSTE
  ACS) who were planned for early
catheterisation.
Methods and Results
 A total of 328 consecutive patients with NSTE ACS were included and were
randomised to pre-treatment with dual (N=166, aspirin, clopidogrel 600 mg) or
triple antiplatelet therapy (N=162, aspirin, clopidogrel 300 mg and tirofiban). The
primary end point was enzymatic infarct size, defined as cumulative LDH release
(LDHQ48). Initial TIMI flow of the culprit vessel was a pre-specified secondary end
point. Angiography was performed in 98% of patients at a median of 23 hours
after admission. Enzymatic infarct size (median, 25-75%) was 166 (60-349) IU/l in
the triple group compared to 193 (75-466) IU/l in the dual group (p=0.2). Initial
TIMI 3 flow of the culprit vessel was significantly more often observed after triple
antiplatelet therapy (67% vs. 47%, p=0.002). At 30 days follow-up, myocardial
infarction occurred in 46% of patients in the triple antiplatelet group, compared to
57% in the dual antiplatelet group, p=0.052. No significant difference in bleeding
was present.
Conclusion
This study showed that in patients with NSTE ACS, triple antiplatelet pre-
treatment was associated with a non-significant reduction in enzymatic infarct
size, a significantly better initial perfusion of the culprit vessel and a trend towards
a better survival without death or myocardial infarction. Further, large scale
studies should be performed to find whether the beneficial trend in favour of triple
antiplatelet pre-treatment can be reproduced.Chapter 2.4
63
Introduction
Previous studies showed that glycoprotein IIb/IIIa blockers improve outcome in
high risk patients with non ST elevation acute coronary syndrome (NSTE
 ACS),
especially in those patients who undergo an early invasive strategy [1-3].
 These
studies however, were performed without the routine co-administration of
clopidogrel. In the past few years, clopidogrel has been shown to be effective as
pre-treatment in patients undergoing angioplasty. These effects were shown both
in patients undergoing elective PCI [4] and in patients with NSTE ACS [5]. In
addition it was found that a loading dose of 600 mg was associated with faster
platelet aggregation inhibition, as compared to the regular 300 mg loading dose
[6]. In the ELISA-1 study, it was shown that a strategy of delayed
 angiography
with concomitant pre-treatment with tirofiban was
  associated with improved
angiographic outcomes and less initial
 enzyme release [7]. These brought us to
compare a dual anti-platelet strategy of aspirin and 600 mg of clopidogrel with a
triple anti-platelet strategy of aspirin, clopidogrel 300 mg and the glycoprotein
IIb/IIIa blocker tirofiban in patients with NSTE
 ACS who all were scheduled for
angiography within 48 hours.
Patients and Methods
Consecutive patients
 with NSTE
 ACS were enrolled in the ELISA-2 trial. Inclusion
criteria were ischemic chest pain classified as Braunwald class 3 and the
presence of at least 1 of the following criteria: new ST depression of more than 1
mm in at least 2 ECG leads or a positive biomarker (cardiac troponin T > 0.05
µg/L, or CK-MB elevation more than upper limit of normal). Patients were
excluded for the following reasons: age > 80, persistent ST segment elevation,
previous percutaneous coronary intervention (PCI) within the preceding 6 months,
cardiogenic shock or a contra-indication for the use of triple antiplatelet therapy or
invasive therapy. All patients were treated with low molecular weight heparin, beta
blockers, statins, nitroglycerin and ACE inhibition when appropriate. After the
patients gave written informed consent they were randomized by a computerised
randomisation procedure. Patients were randomised to either pre-treatment with
dual (aspirin, clopidogrel 600 mg) or triple antiplatelet therapy (aspirin, clopidogrel
300 mg and tirofiban 10 microgram/kg bolus, 0.15  microgram/kg/min
maintenance) (Figure 1). ELISA-2 trial
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Figure 1: Study flow chart
Study medication was given in an open label manner. All patients were scheduled
for coronary angiography within 48 hours after admission. Type of
revascularisation, PCI or coronary artery bypass grafting (CABG), was left at the
discretion of the operator. In the triple antiplatelet group, tirofiban was continued
for 12 hours in case PCI was performed.  
Upstream tirofiban bailout in the dual antiplatelet patients was defined as,
initiation of tirofiban because of recurrent or persistent ischemia before
angiography. The bailout use of tirofiban downstream was left at the discretion of
the operator. Event free survival was defined as freedom of death or myocardial
infarction. The primary end point was enzymatic infarct size. Initial TIMI flow of the
culprit vessel was a pre-specified secondary end point. Both end points were
LMWH, Beta-Blocker and Statin
Randomization N =328
Dual antiplatelet
 (aspirin, clopidogrel 600 mg)
N= 166
Did not receive allocated treatment N = 3
Triple antiplatelet
(aspirin, clopidogrel 300 mg, tirofiban)
N= 162
Did not receive allocated treatment N= 0
Angiography N= 162
12-48 hours later
Assessed for eligibility N =448
NSTE ACS
Chest pain and elevated biomarkers or ST deviation
Excluded N = 120
Not meeting inclusion criteria or
refused participation
Angiography N = 159
Enzymatic infarct size analyzed N = 129
Not analyzed N = 37
Early discharge N= 21
No CAD N = 9
Not measured N= 7
Enzymatic infarct size analyzed N= 127
Not analyzed N = 35
Early discharge N= 13
No CAD N= 13
Not measured N= 9Chapter 2.4
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analyzed by an independent core lab (Diagram B.V., Zwolle, The Netherlands) by
technicians who were unaware of the clinical data. 
Enzyme Release and Enzymatic Infarct size
Blood samples were obtained on admission and every 6-12 hours hereafter up to
72 hours. In case PCI was performed later than 72 hours after admission, cardiac
enzymes were measured at 6 and 12 hours after PCI. Enzymatic infarct size
(LDHQ48) was calculated based upon enzyme concentrations of Lactate
Dehydrogenase (LDH) as the reference enzyme, in which an area under the
curve was calculated from at least 5 measurements. A two-compartment model
was used, which has been validated in studies on the turnover of radio labeled
plasma proteins and circulating enzymes [8-10]. In addition, as an alternative
assessment of enzymatic infarct size, peak creatin kinase (CK) was defined as
the highest level of CK during admission, with the exception of patients who
underwent CABG during the index hospital admission. 
Angiographic data analysis
All angiograms were analyzed by an independent core lab without knowledge of
clinical data. TIMI flow grades of the culprit vessel were assessed before and
after the angioplasty procedure, as previously described [11].
 
Clinical Outcome  
Total death and myocardial infarction were assessed at 30 day follow-up.
Myocardial infarction was defined as a CK-MB elevation of more than 6% of total
CK, whenever CK was above 200 U/l (men) or above 170 U/l (women). After
CABG, myocardial infarction was defined as the development of new Q waves on
the post CABG electrocardiogram. Major bleeding was defined as the need for at
least 2 units of blood and a fall in haemoglobin of more than 2 mmol/l, corrective
groin surgery, gastro-intestinal, cerebrovascular haemorrhage or retro peritoneal
bleeding.
Statistical analysis
Sample Size calculation
Sample size calculation was made based on the findings of ELISA-1 trial [7]. Our
hypothesis was that a strategy of triple anti platelet therapy would reduce
enzymatic infarct size by 30%. It was calculated, assuming an infarct size of 500
IU/l for the dual and 350 IU/l for the triple antiplatelet group with a standard
deviation of 500 and assuming normal distribution of enzymatic infarct size, thatELISA-2 trial
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330 patients were needed to prove superiority of triple over dual anti-platelet
therapy with a power of 80% and assuming a type I error of 5%. 
Final Analysis
The primary end point was compared using the Mann Whitney test and expressed
as median and 25 -75 percentiles. The secondary end point, initial TIMI 3 flow of
the culprit vessel, was compared using Chi square analysis. The Fisher’s exact
test was used when the expected cell value was < 5. Data were analysed
according to the intention to treat principle. The difference in the occurrence of
death or myocardial infarction between the groups during 30 day follow-up was
assessed by the Kaplan-Meier method using the log-rank test. A p value < 0.05
was considered statistically significant. All tests were two-sided.
Results
From September 2002 to January 2005, 328 patients were included, 166 were
randomised to dual, 162 to triple antiplatelet therapy. Baseline characteristics
were not different between the groups (Table 1), except for a higher age in the
dual antiplatelet group (65 vs. 62 years, P=0.008). Seventy eight percent of
patients had a positive troponin T at the time of inclusion and 61% had at least 1
mm of ST depression at electrocardiography on admission. Angiography was
performed in 98% of patients after a median of 23 hours after admission, without
a difference between the groups (P = 0.9). 
Primary and secondary end points
Enzymatic infarct size as assessed by LDHQ48 or Peak CK is shown in Table 2
and Figure 2 and could be assessed in 256 (78%) and 327 (99,9%) patients,
respectively. LDHQ48 median was 166 in the triple vs. 193 IU/l in the group who
received dual pre-treatment, (relative reduction (RR): 14%, p=0.2). Peak CK was
216 IU/l in the triple antiplatelet group and 261 IU/l in the dual antiplatelet group
(RR 17%, p=0.3). Chapter 2.4
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Table 1: Baseline and angiographic data
Dual Triple
Variable                                              (n= 166)                                  (n= 162)                 P-value
Age (yrs ± SD)  65 ± 10 62 ± 11 0.008
Female Gender, n (%) 46 (28) 49 (30) 0.6
Diabetes Mellitus, n (%) 33/165 (20) 24/159 (15) 0.2
Hypertension, n (%) 81/159 (51) 70/151 (46) 0.4
Smoking, n (%) 64/146 (44) 59/146 (40) 0.6
Hypercholesterolemia, n (%) 62/143 (43) 53/137 (39) 0.4
Previous MI, n (%) 33/166 (20) 36/162 (22) 0.6
Previous PCI, n (%)  30/166 (18)   35/162 (22)  0.4
Previous CABG, n (%)  26/166 (16)  16/162 (10)  0.1
Symptom onset- admission 2.9 (1.8-5.5)    2.6 (1.6-6.8)  0.7 
Median (25-75 percentile)(hrs)  
Admission – angio     22.5 (15.1-30)   22.2 (15.3-29) 0.3
Median (25-75 percentile)(hrs)  
Urgent angio, n (%)  32/159 (20)    28/152 (18)  0.7
Syst BP (mmHg)    149 ± 27  144 ± 24  0.1
Troponin T> 0.05 ng/ml n, %   115 (71) 98 (63) 0.1
TIMI risk score, mean ± SD 2.9 ± 1.4 2.9 ± 1.3 0.8
ST depression > 1 mm, n, %             99 (61)                                      99(62)                           0.9
MI= myocardial infarction, PCI= percutaneous coronary intervention, CABG= coronary artery bypass
grafting, Syst BP= systolic blood pressure
Table 2:  Enzyme release 
Dual Triple
Variable                                  (n= 166)                                  (n= 162)                 P-value    
Peak CK (IU/L)   261 (114 – 508 )       216 (93 – 480) 0.3
Peak CK-MB (IU/L)   33 (19 – 70)   27 (17.5 – 55) 0.2
LDHQ48 (IU/L)                       193 (75-466)                           166 (60-349)               0.2       
CK= creatine kinase, CK-MB= creatine kinase MB mass, LDHQ48 = Enzymatic infarct size (area under
the lactate dehydrogenase release over 48h curve) Data are expressed as median and 25-75
percentiles
Table 3 shows the angiographic parameters. Initial TIMI flow could be assessed
in 248 out of 281 (86%) patients with a confirmed diagnosis of an acute coronary
syndrome. Initial TIMI 3 flow of the culprit vessel was present in 67 % in the triple
antiplatelet group, as compared to 47% in the dual antiplatelet group (P = 0.002).
At initial angiography, thrombus was present in 6% in the triple antiplatelet group
compared to 11% in the dual antiplatelet group (p = 0.1).  ELISA-2 trial
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Figire 2: Enzymatic infarct size
Table 3: Angiography
Dual Triple
Variable                                              (n= 166)                                  (n= 162)                  P-value
Angio performed, n (%)  162 (98)   159 (98)  1.0
Number of vessel disease, n (%)  
0    17/162 (11)   23/159(15)  0.3
1     54/162 (33)   55/159(34) 0.8
Multi vessel   89/162 (55)  78/162 (49)  0.3
Left main   2/162 (1)   3/159(2) 0.7
TIMI flow culprit pre, n (%)   
3   62/131 (47)   79/118 (67) 0.002
0-2 69/131 (53) 39/118 (33)
Thrombus initial angio   16/145 (11)  8/135 (6) 0.1
Indication, n (%) 
Conservative no vessel disease   17/162 (10)   23/159 (14)   0.3
    Conservative   21/162 (13)   19/159 (12)  0.8
    PCI   100/162 (62)   89/159 (56)   0.3
    CABG   24/162 (15)   28/159 (18)    0.5
   Stenting   86/100 (86)   71/86 (83)   0.5
TIMI flow post, n (%)  
0-2 9/100 (9) 3/86 (4) 0.1
            3                                              91/100 (91)                             83/86 (97)                   0.1
TIMI = Thrombolysis in Myocardial Infarction, PCI = percutaneous coronary intervention,
CABG= coronary artery bypass graftingChapter 2.4
69
After multivariate analysis, correcting for all parameters which were borderline
different (P<0.10) between the 2 groups (table 1), the results of the primary and
secondary end point did not change, no significant effect was found on enzymatic
infarct size, OR: 0.85: 95% CI: 0.52-1.40; P = 0.6, however triple antiplatelet pre-
treatment remained independently associated with a higher initial patency of the
culprit lesion, OR: 2.5, 95% CI: 1.5-4.4; P = 0.001. Percutaneous coronary
intervention and CABG were performed equally in both groups. TIMI 3 flow after
PCI was 97% vs. 91% in the triple and dual antiplatelet group, respectively (p =
0.10). 
Bail-out use of tirofiban
Bail-out tirofiban was used in 37 patients (22%) allocated to the dual antiplatelet
group. In 8 patients (5%) upstream tirofiban was given because of persistent
symptoms of ischemia before angiography. Another 29 patients (17%) were
treated with tirofiban after angiography or PCI (downstream). 
Medication
On discharge the fast majority of the patients received aspirin, beta blockers,
statins and clopidogrel (Table 4).
Table 4: Discharge medication
Dual Triple
Variable                                              (n= 162)                      (n= 159)                   P-value     
Aspirin, n (%) 140 (86) 143 (90) 0.3
Beta-Blocker, n (%)                             138 (85) 137 (86) 0.8
Statin, n (%)                                        134 (83) 119 (75) 0.08
Clopidogrel, n (%)                               108 (67)    100 (63) 0.5
ACE inhibitor, n (%)                             66 (41) 57 (36) 0.4
Diuretics, n (%)                                    20 (12) 22 (14) 0.7
Oral anti-coagulation                           13 (8)                        13 (8)                            1.0       
Clinical outcome
Table 5 shows 30 day outcomes. Thirty day follow up was available in 325 (99%)
of patients. Death or myocardial infarction at 30 day follow-up occurred in 46% of
patients in the triple antiplatelet group, as compared to 59% in the dual
antiplatelet group (p=0.052) (Figure 3) according to the intention to treat analysis.
Whether myocardial infarction was present on admission or occurred later as
evolving or peri-procedural is given in Table 5 as well. Three patients had a
myocardial infarction on admission as well as after PCI and were counted in both
groups.  ELISA-2 trial
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Table 5: Patient outcomes at 30-day
Dual Triple
Variable                                              (n= 163)                      (n= 162)                   P-value  
Death, n (%) 1 (1)   1 (1)   1.0
Infarction, n (%) 93 (57) 75 (46) 0.052
Admission 42(26) 33(20)
Evolving 40 (25) 33(20)
Peri-PCI 11(7) 7 (4)
Re-infarction 1(1) 2(1)
Death or infarction, n (%) 93 (57)   75 (46)   0.052
Stroke, n  0 0 1.0   
Bleeding, n (%) 16 (10) 20 (12) 0.5
CABG related, n (%) 10 (6) 14 (9) 0.69
           Surgical re-exploration           2 (20)                            4 (29)                            1.0       
P = 0.098
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Figure 3A: 96-hour event free survival
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Safety
Sixteen patients (10%) in the dual group and twenty patients (12%) in the triple
group had major bleeding complication (P = 0.5). CABG related bleeding occurred
in 10 and 14 patients, respectively. Six patients underwent surgical re-exploration
because of tamponade. Intracranial haemorrhage did not occur in either
treatment.
Discussion
This is the first study that compared an oral antiplatelet drug regimen of aspirin
and high dose clopidogrel to a drug regimen containing aspirin, clopidogrel and
intravenous tirofiban as upstream therapy in patients with non ST segment
elevation acute coronary syndrome, who were all scheduled for early
angiography. Only a small, non-significant decrease of enzymatic infarct size
(primary endpoint) was observed after triple antiplatelet therapy. However, initial
TIMI 3 flow of the culprit vessel, a pre-specified secondary end point, was also
more often present in patients pre-treated with the triple antiplatelet regimen.
0 10 20 30
               Time (days)
0
20
40
60
80
100
E
v
e
n
t
 
f
r
e
e
 
S
u
r
v
i
v
a
l
 
(
%
)
P = 0.08
Dual
Triple
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This is in accordance with the findings of the ELISA-1 study [7]
 and the PRISM
plus angiographic sub study [12] which found a better initial perfusion and a lower
presence of thrombus of the culprit vessel in patients pre-treated with tirofiban as
compared to no tirofiban. In the latter study, the difference in angiographic
outcome closely paralleled differences in clinical outcome.
The beneficial value of upstream use of glycoprotein IIb/IIIa inhibitors on reduction
of thrombus and improvement of initial patency has been described earlier,
however, it is questionable whether the improved angiographic outcome pre-PCI
translates into a better outcome after PCI. A TACTICS-TIMI 18 sub study showed
that longer pre-treatment with tirofiban was associated with improved pre- and
post-PCI myocardial perfusion [13]. Also the PRISM plus angiographic sub study
found that initial TIMI 3 flow was associated with a better post-PCI TIMI flow [12].
In our study, there was a trend towards a better post-PCI TIMI flow in patients
treated with triple antiplatelet pre-treatment. 
Enzymatic infarct size in NSTE ACS
In patients with NSTE ACS, changing the definition of myocardial infarction may
have important consequences. This was recently shown in the ICTUS trial, where
outcome was different when the TACTICS criteria for myocardial infarction were
used [14]. In our study however, outcome did not change when the 3 times upper
limit of normal value was used as cut-off. In Table 5, myocardial infarction is given
depending on the time of occurrence. Evolving myocardial infarction tended to
occur less often in the patients allocated to triple antiplatelet pre-treatment,
however, peri-procedural infarction may be masked by the presenting acute
coronary syndrome, especially when PCI is performed very early after admission.
This is why we chose enzymatic infarct size over a period of time. This takes total
enzyme release over a period of time into account and may better quantify
 the
effect of distal micro-embolization, especially in patients
 whose enzymes have not
returned to normal values on the moment
 of intervention. Elisa-1 showed that by
using total enzyme
 release over a period of time, it was possible to detect an
effect of treatment, which not became evident when the incidence
 of (recurrent)
myocardial infarction was assessed only [7].
  Previous studies which also
evaluated enzymatic infarct size in patients with NSTE ACS found that enzymatic
infarct size well correlated with clinical outcome [15].
Comparison with other studies
In previous studies which compared dual with triple antiplatelet pre-treatment,
patients with acute coronary syndromes were excluded. The ISAR-REACT trialChapter 2.4
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performed in patients undergoing elective PCI, did not find a difference in
outcome between the groups [16]. The CLEAR PLATELETS study showed that,
in elective stenting, use of a GP IIb/IIIa inhibitor on top of clopidogrel produced
superior platelet inhibition and lower myocardial necrosis compared with high-
dose (600 mg) or standard-dose (300 mg) clopidogrel alone [17]. In our study, in
patients with non STE ACS, the addition of tirofiban to aspirin and clopidogrel was
associated with a non significant trend towards a better outcome and a beneficial
effect on angiographic outcome. However, due to the small sample size of the
trial, it is not possible to draw definite conclusions from our study. With the
present level and difference of enzymatic infarct size between the groups, around
2.310 patients would have been needed to demonstrate a significant difference.
The ongoing early ACS study, with a comparable design as ELISA-2, has planned
to include more than 10.000 patients, to find a difference in a combined clinical
end point [18].
 Therefore, according to these results, there is no reason to change
the most recent guidelines on PCI which recommend both clopidogrel 600 mg
and a glycoprotein IIb/IIIa inhibitor in high risk patients with ACS undergoing PCI
[19].
Safety 
No significant difference in bleeding was observed between the 2 groups and
intracranial haemorrhage did not occur in either treatment. However, among
CABG treated patients 10 out of 24 in the dual and 14 out of 28 in the triple
antiplatelet treated patients had procedural bleedings. In 18 patients a fall in
haemoglobin of more than 2 mmol/l requiring blood transfusion was present. In 6
patients, surgical re-exploration was performed because of pericardial
tamponade. Despite this relatively high incidence of bleeding, clinical outcome
was good in the patients who underwent CABG. So far, there are no large trials
with concomitant use of GP IIb/IIIa inhibitor and high dose clopidogrel in NSTE
ACS patients. The ISAR-REACT trial [16], in patients undergoing elective PCI
showed no difference in major or minor bleeding, however, the incidence of minor
bleeding complications, i.e. thrombocytopenia
  and the transfusion
  of blood
products, was higher in the triple group. Also the CLEAR PLATELETS study
showed no difference in bleedings complication between dual and triple
antiplatelet therapy [17]. To draw definitive conclusions on the safety of triple
antiplatelet therapy in high risk ACS patients, larger scale clinical trials are
needed.ELISA-2 trial
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Limitations
The dose of clopidogrel in the triple antiplatelet group was 300 mg, compared to
600 mg in the dual group. The lower dose was chosen because no data existed
on the combination of intravenous tirofiban and 600 mg clopidogrel on a possible
higher risk of bleeding at the moment the study was designed in 2001. However
Gurbel et al
17 found that platelet inhibition dose not differ when a glycoprotein
IIb/IIIa inhibitor is combined with either 600 mg or 300 mg clopidogrel. Another
limitation of the study is that LDHQ48 is not an established end point in NSTE ACS
trials. However, previous trials showed that enzymatic infarct size is well
correlated with clinical parameters [15,20]. Furthermore, in this study there was a
slight difference in baseline characteristics, however, after performing a
multivariate analysis correcting for the borderline differences between the two
groups (P<0.10), the results of primary and secondary endpoints did not change.
Finally, enzymatic infarct size was not calculated in 22% of the patients (Figure
1), however in these patients median CK’s were not different between the two
groups, (135 (80-269) and 124 (71-226) in the dual and triple group, respectively).
Conclusion
This study showed that in patients with NSTE ACS, triple antiplatelet therapy was
associated with a non-significant reduction in enzymatic infarct size, a significantly
better initial perfusion of the culprit vessel and a trend towards a better survival
without death or myocardial infarction. This study supports the current guideline
18
that recommend use of both clopidogrel and a GP IIb/IIIa inhibitor in high risk
patients with a non ST elevation acute coronary syndrome planned for invasive
therapy.Chapter 2.4
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Abstract
Background: Guidelines are mainly based upon results of randomised controlled
clinical trials. However, due to low external validity of these trials, their results can
not reasonably be applied to all patients in routine practice. In our hospital, all
patients with ST-elevation myocardial infarction (STEMI) are eligible for inclusion
in one of our ongoing trials or registries. To asses differences between patients
enrolled versus not enrolled in a trial or registry, we evaluated all patients with a
discharge diagnose of STEMI during the study period. 
Methods:  Retrospectively, individual patient data from all patients with a
discharge diagnosis of STEMI between Jan 2001 and Dec 2001 were evaluated.
Follow-up data were obtained until Dec 2004.
Results A total of 583 patients were discharged with a diagnosis of STEMI. 455
patients (78%) were enrolled in one of the ongoing clinical trials or registry and
128 were not.  Not enrolled patients were significantly older, more often had a
history of previous MI and had higher risk profiles.  Multivariate analysis revealed
that higher age was the only independent predictor for non enrolment. Not
enrolled patients were more often treated conservatively and had a higher
mortality rate (36% vs. 6%, p <0.001). After multivariate analysis, non enrolment
(OR: 95% CI) 4.02 (1.98-8.16), age 1.07(1.04-1.12) and diabetes 2.39 (1.17-4.89)
were the only independent predictors of long term mortality.
Conclusion This study shows important differences in baseline characteristics,
treatment and prognosis between patients with STEMI who were enrolled or not
in a trial. To better reflect daily clinical practice, guidelines should also consider
results of observational studies of unselected patients.Chapter 3.1
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Introduction
Although guidelines are mainly based on results of randomized controlled clinical
trials (RCTs), it has been recognized that patients enrolled in these trials may not
reflect those seen in daily clinical practice [1,2]. Only few studies have described
external validity of trials with ST-segment elevation myocardial infarction (STEMI)
patients [3,4]. This may be even more important since also voluntary based
registries report on a selected patient population [5-7].
 For more than 15 years, a
number of trials on treatment of STEMI have been performed in our hospital [8-
10]. Since all patients with STEMI in our hospital are considered for inclusion in
one of our clinical trials [11,12] we had the opportunity to evaluate all patients
admitted with STEMI and compare those enrolled in a trial or registry with patients
not enrolled.
Methods
Population 
From 01 January 2001 to 31 December 2001, individual patient data from all
patients with the discharge diagnosis of STEMI at our hospital were recorded. To
avoid double inclusion of patients, only the first recorded admission for STEMI
during the study period was used. Patients were diagnosed with STEMI if they
had chest pain of > 30 minutes duration and ECG changes with ST segment
elevation > 2 mm in at least 2 precordial and > 1 mm in the limb leads. 
Data collection and follow-up
We collected the following variables from the patient files:
 age, gender, history of
hypertension, diabetes, hyperlipidemia, smoking, previous myocardial infarction
(MI) and discharge medication. Follow-up information was obtained from the
patient's general physician or by direct telephone interview with the patient.
Enrolled patients consisted of both patients included in a trial, either a randomised
clinical trial or registry, whereas not-enrolled patients were those who were
neither included in a RCT or in a registry. Registry patients consisted of patients
with STEMI who met the in- and exclusion criteria of ongoing trials, but for
unknown reason were not included in a trial.
Definition
Unjustly not-enrolment was defined as patients who were not enrolled in the trial
despite being eligible. Unjustly conservative treatment was defined as patients
who should have been treated with an invasive strategy according to the
guidelines [13],
 but were treated conservatively.External validity of clinical trials                                                                                        
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Statistical analysis 
Statistical analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean and categorical data as
percentage, unless otherwise denoted. The analysis of variance and the chi-
square test were appropriately used for continuous and categorical variables
respectively. A multivariate logistic regression analysis was performed to identify
independent predictors of non enrolment in trial and a multivariate logistic
regression analysis for predictors of mortality. Significant variables analyzed are
reported with their respective odd ratios and 95% confidence intervals (CI). For all
analyses, statistical significance was assumed when the two tailed probability
value was < 0.05. 
Results
During the study period, 583 patients were discharged with a diagnosis of STEMI.
A total of 455 (78%) patients were enrolled in a clinical trial or registry and 128
(22%) were not. 
Baseline characteristics
Baseline characteristics are summarized in Table 1. Patients who were not
enrolled in a clinical trial were significantly older, more often female, had more
often diabetes and had more often hypertension or a history of previous MI (Table
1). Hyperlipidemia and smoking were significantly more common in patients who
were enrolled in a clinical trial or registry (Table 1). No difference in baseline
characteristics and outcome was found between the clinical trial enrolled and
registered patients.
Table 1: Baseline  
Variable                                  enrolled             n                    not enrolled      n                 P-value
Age, Y, Mean ± SD 61.5 ± 12 455 69.1 ±12 128        < 0.001
Female gender, n (%)  110 (24) 455   40 (32) 128 0.06 
Diabetes, n (%)  55 (12) 455 25 (22)     113 0.006
Hypertension, n (%)  146 (35) 416  53 (47)      113 0.015
Hyperlipidemia, n (%)  102 (35) 293  24 (21)     113 0.005
Smoking, n (%)  212 (48) 446 39 (35)      112 0.010
Previous MI, n (%)                    53 (12)           454                   28 (23)           124                  0.002
MI= myocardial infarctionChapter 3.1
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Treatment and outcome 
Cardiac catheterization and percutaneous coronary intervention were less often
performed in the not enrolled patients (Table 2). Coronary artery bypass grafting
(CABG) was performed more often in the not enrolled patients,  8% vs. 3%, p =
0.02. 
Table 2: Treatment and outcome
Variable                                  enrolled             n                    not enrolled      n                P- value
CAG (%) 454 (99.8) 455 87 (68) 128          <0.001
PCI, n (%)  415 (92)* 453 66 (76)* 87          <0.001
Thrombolysis, n (%) - - 9 (7) 128 -
CABG, n (%)  13 (3) * 453  7 (8) * 87 0.02
Conservative, n (%) 25 (5) 455 46 (36) 128          <0.001
Death, n (%)                           27 (6)                453                  44 (36)              121               <0.001
CAG = coronary angiography, PCI= percutanous coronary intervention, CABG: coronary
artery bypasses grafting, * = of patients with CAG.
At discharge, not enrolled patients less frequently received aspirin, clopidogrel or
a statin than enrolled patients. Beta blockers and ACE-inhibitors were prescribed
equally in both groups (Table 3).
 Table 3: Discharge medication
Variable                                  enrolled           n                      not enrolled     n          P-value
Aspirin, n (%) 389 (87) 447 84 (79) 106 0.041
Beta blocker, n (%) 393 (88) 447 91 (86) 106 0.56
Clopidogrel, n (%) 337 (75) 447 45 (43) 106 <0.001
Statins, n (%) 310 (70) 447 46 (43) 106 <0.001
ACE-inhibitor, n (%)               239 (54)          447                  61 (58)              106      0.45
n = number of patients 
At 3 year follow up, 36% of the patients in the not enrolled group had died versus
6% (p<0.001) in the trial enrolled or registered patients (Figure 1) 
Reasons for not-enrolment       
Of the 128 not enrolled patients, 75 (59%) patients were potential trial candidates,
but unjustly not enrolled. The reasons for justly not-enrolment were: age above
eighty (17%), cardiopulmonary resuscitation (CPR) (8%), serious co-morbidity
(13%), too late presentation after symptom onset (4%) and 2 patients (2%)
refused participationExternal validity of clinical trials                                                                                        
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Multivariate analysis
To assess independent predictors of non enrolment in a clinical trial, we
performed a multivariate analysis and included age, gender, diabetes,
hypertension, smoking and previous MI. The multivariate analysis revealed age
as the only independent predictor (Table 4). 
Figure 1:  Kaplan Meier survival curve. Patients with STEMI not enrolled in a clinical trial, had
significantly higher mortality rates at 3 year follow up.
Enrolled
Not-enrolled
P < 0.001
Enrolled
Not enrolledChapter 3.1
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Table 4: Multivariate analysis: predictors of nonenrolment in trials
Variable                       OR (95 CI)                             P- value
Age 1.04 (1.01-1.06) 0.005
Female 0.83 (0.49-1.40) 0.48
Hypertension 1.76 (1.90-2.86) 0.22
Previous MI 1.44 (0.79-2.63) 0.24
Diabetes 1.58 (0.86-2.91) 0.14
Hyperlipidemia           0.54 (0.31-0.95)                       0.33                 
MI= myocardial infarction
To assess independent predictors of mortality we performed another multivariate
analysis and included non enrolment in clinical trial, age, diabetes, hypertension,
smoking and previous MI, conservative treatment and no PCI performed. The
independent predictors of mortality were non enrolment in a trial (OR 95% CI)
4.02 (1.98-8.16), age 1.07(1.04-1.12) and diabetes 2.38 (1.17-4.89) (Table 5). 
 
Table 5: Multivariate analysis: predictors of mortality
Variable                       OR (95 CI)                              P- value         
Non trial 4.02 (1.98-8-16) < 0.001
Age, per year 1.07 (1.04-1.12) < 0.001
Diabetes 2.38 (1.17-4.89) 0.017
Hypertension 1.71 (0.90-3.23) 0.099
Previous MI 1.81 (0.85-3.85) 0.12
Smoking 1.24 (0.57-2.70) 0.59
No PCI 1.13 (0.28-4.27) 0.88
Conservative                1.62 (0.39-6.67)                       0.51                 
MI= myocardial infarction, PCI = percutanous coronary intervent
Discussion
This study identifies important differences in patient characteristics, management
and outcome among patients discharged with the diagnosis of STEMI enrolled or
registered versus not enrolled in a clinical trial or registry.
Trial versus non Trial 
This study showed, in accordance with previous thrombolytic trials [14,15,16,17],
that patients at higher age, female gender, and patients with multiple risk factors
were less often enrolled in trials. This has been observed in older trials as well
[18]. 
Diabetes, history of previous MI and hypertension were more common in the not
enrolled patients (Table 1). Cardiac catheterization and revascularization wereExternal validity of clinical trials                                                                                        
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performed less frequently in the not enrolled patients. Long term mortality rates
were considerably higher in the not enrolled patients even after multivariate
analysis. 
Reasons for not-trial enrolment
Several reasons for recruitment of low-risk patients into clinical trails have been
suggested. Exclusion criteria are the clearest reason [14].
 Other reasons may be
stroke and CPR before admission [19]
 and admission during off-office hours. The
latter might be explained by the limited time for and experience of recruiting
patients into a clinical trial for the single doctor on call during nights and
weekends [15].
  In our trial, higher age, CPR, co-morbidity and too late
presentation were among the reasons for not-enrolment.
Unjustly not-enrolment or unjustly conservative treatment may also be one of the
reasons for worse outcome among not-enrolled patients. Of the 128 STEMI not
enrolled patients 79 (59%) were potential trial patients but unjustly not enrolled.
Of the 46 not enrolled patients who were treated conservatively, 17 (37%) were
treated unjustly, according to the ESC guidelines. In the majority of the patients,
no clear reason could be assessed for unjustly not-enrolment or unjustly
conservative therapy. 
Reason of different outcomes 
Potential explanations for these differences in mortality rates may due to the fact
that, not enrolled patients were older, had higher risk profiles, were more often
treated conservatively and less frequently received guide-line recommended
medication on discharge. Our results are in accordance with a previous study,
showing that an early invasive management strategy is not utilized in the majority
of high-risk patients [20].
 This strategy appears to be reserved for patients without
significant co-morbidities and with a lower risk of in-hospital mortality.
 However, in
patients older than 75 years of age, a routine early invasive strategy can
significantly improve clinical outcomes [8].
External validity
Clinical relevance and applicability of RCTs depends on external validity, that is,
whether the results can be generalized to broader group of patients. Many RCTs
have low external validity and therefore their results can not be reasonably
applied to patients in routine practice [21].
  Nevertheless, large scale RCTs
provide the most reliable data on the effects of treatment and many serious errorsChapter 3.1
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have resulted from relying on other types of evidence [21]. Results of not-
randomized studies are suggested to be more externally valid than RCTs
because they include all patients and are done in a real world setting [22,23].
 The
outcome of the trial enrolled patients in our study is only valid for patients who
met the in- and exclusion criteria of the trials [8,9].
Conclusions
This study shows important differences in baseline characteristics, treatment and
prognosis between STEMI patients who were enrolled or not in a trial. The need
for a more representative enrolment in trials with STEMI is warranted. Due to
recruitment of lower-risk patients into clinical trials, the external validity of these
trials may be limited. To better reflect daily clinical practice, guidelines should also
consider results of observational studies of unselected patients.External validity of clinical trials                                                                                        
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 Abstract
Aim:  Circumflex (CX) artery related myocardial infarction (MI) is less well
represented in trials on ST elevation acute myocardial infarction (STEMI), most
often due to absence of significant ST segment elevation and therefore, outcome
of these patients is less well known. We aimed to compare the outcome of
patients with CX versus right coronary artery (RCA) related STEMI in a large
cohort of patients treated with primary angioplasty. 
Methods and results: A total of 1.683 consecutive patients with STEMI were
studied. Patients who lacked ST segment elevation were also included if they had
persistent chest pain with signs of ischemia or regional wall motion abnormalities
on echocardiography. Coronary angioplasty was performed according to standard
procedures. After the intervention, all patients received aspirin and clopidogrel or
ticlopidine. 
Results: The infarct related vessel (IRV) was the CX in 229 patients (14%) and
the RCA in 600 patients (36%). No differences in baseline characteristics were
present. Mean extent of ST segment elevation or deviation was significantly
higher in patients with the RCA as IRV. Enzymatic infarct size was significantly
higher in the CX related MI (1.338 ± 1.117 IU/l vs. 1.806 ± 1.498 IU/l, p<0.001).
Left ventricular ejection fraction <45% was more often present in patients with CX
related MI (37 vs. 26%, p<0.01). Both short- and long-term mortality were
significantly higher in the CX related MI. 
Conclusion: This study emphasizes the fact that CX related infarction has a
worse prognosis compared ro RCA related infarction.                                                                                                                                                             Chapter 3.2
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Introduction
Acute myocardial infarction is caused by plaque rupture in one of the three
coronary vessels [1]. The outcome of patients with acute myocardial infarction is
well known for patients in whom the RCA or LAD is involved, however the
prognosis of CX related myocardial infarction is less clear. Circumflex related
myocardial infarction is less well represented in large randomised trials on ST
segment elevation acute coronary syndromes. In these studies less than 20% of
recruited patients have the CX as culprit lesion [2,3]. Many CX related infarctions
are missed due to limited or absent ST segment elevation. In addition, it is known
that reperfusion therapy is given in only 60% of patients with ST segment
elevation myocardial infarction [4]. One of the main reasons for withholding
reperfusion therapy in these patients is the presence of limited ECG abnormalities
(non-diagnostic ECG). Thrombolysis is often not given in patients with a non-
diagnostic ECG. However, immediate angiography and subsequent primary
angioplasty may be more easily performed in patients with a clinical suspicion of
myocardial infarction without clear ST segment elevation on the admission ECG.  
This study compares the outcome of patients with CX versus RCA related acute
myocardial infarction in a large cohort of patients treated with primary angioplasty.
Methods
The study population has been described previously [5]. In brief, 1.683 patients
with more than 30 minutes of chest pain together with ST segment elevation of at
least 1 mm in 2 consecutive leads were included.  Patients whose symptoms
began between 6 to 24 hours before admission or who lacked ST segment
elevation were also included if they had persistent chest pain or signs of ischemia
or had regional wall motion abnormalities on echocardiography. Only refusal of
consent or death was exclusion criteria. All patients were treated with aspirin (500
mg i.v.) and unfractionated heparin (5.000-10.000 IU i.v.) before coronary
angiography. Coronary angiography and angioplasty were performed according to
standard procedures. After the intervention, all patients received aspirin and
clopidogrel or ticlopidine for at least one month.
Electrocardiographic and angiographic analysis
All electrocardiographic and angiographic analyses were performed by an
independent core lab (Diagram, Zwolle, the Netherlands) by technicians who
were unaware of clinical data. Cumulative ST segment elevation and deviationOutcome in CX related MI                                                                                               
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and the presence of rhythm or conduction disturbances were assessed as
previously described [6]. The infarct related vessel was determined based upon
the aspect of the lesion together with the location of ECG abnormalities.
Quantitative coronary angiography was performed before and after PCI as
previously described [5]. Successful angioplasty was defined as TIMI 3 flow of the
infarct related vessel in combination with a less than 50% residual stenosis (core
lab analysis).  
Enzymatic Infarct Size and Left Ventricular Ejection Fraction
The techniques for assessment of both parameters have been described
previously [7]. In brief, enzymatic infarct size was calculated as the area under the
LDH release curve during a period of 48 hours after admission. In addition, as an
alternative assessment of enzymatic infarct size, peak creatin kinase (CK) and
peak CK-MB (defined as the highest level of CK, CK-MB respectively, during
admission) were assessed. The left ventricular ejection fraction was assessed by
using a radionuclide technique based upon the labelling of red cells with
technetium. This was done before discharge of the patient. 
Clinical outcome
Clinical follow-up was performed at 30 days and at 1-year follow-up by planned
follow-up visits or telephonic interview. For patients who died, hospital records
and necropsy data were reviewed. No patient was lost to follow-up.
Statistical Analysis
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean and categorical data as
percentage, unless otherwise denoted. The analysis of variance and the chi-
square test were appropriately used for continuous and categorical variables
respectively. The Fisher’s exact test was used when the expected cell value was
<5. Data were analysed according to the intention to treat principle. The
difference in survival between groups during the follow-up period was assessed
by the Kaplan-Meier method using the log-rank test. A p value <0.05 was
considered statistically significant.
Results
In 26 of the 1683 patients, the infarct related vessel could not be determined. The
infarct related vessel was the CX in 229 patients (14 %), the RCA in 600 patients
(36 %), the LAD in 786 patients (47 %), the left main in 19 patients (1.0 %) and a                                                                                                                                                           Chapter 3.2
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graft in 23 patients (1.4 %). In this study, patients with the CX as infarct related
vessel were compared with patients with the RCA as infarct related vessel and
therefore the cohort of 829 patients forms the basis of this report.
Baseline clinical characteristics are described in Table 1 and are not different
between the groups. No difference in Killip class on presentation was present
between the groups. Ischemic time, patient delay and door to balloon time were
similar (Table 1). 
Table 1: Baseline, according to infarct related vessel
RCA CX P-value
                                                            (N=600)                        (N=229)                                    
Age (Yrs ± SD) 61 ± 11 60 ± 12 NS
Male Gender 75% 79% NS
Diabetes 11% 11% NS
Hypertension 30% 27% NS
Smoking 49% 55% NS
Pos family history 42% 44% NS
Previous myocardial infarction 12% 11% NS
Previous PCI 7% 4% NS
Killip class 1 92% 93% NS
Ischemic time (hrs) 4.5 ± 3.7 4.8 ± 3.9 NS
Patient delay (hrs) 3.5 ± 3.5 3.6 ± 3.6 NS
Door to balloon time (hrs)                  1.0 ± 0.9                       1.1 ± 0.6                       NS       
RCA = right coronary artery, CX = circumflex, PCI = primary coronary intervention, 
CABG = coronary artery bypass grafting 
The electrocardiographic and angiographic parameters are shown in Table 2. The
mean extent of ST segment elevation or deviation was significantly higher in
patients with the RCA as infarct related vessel. Q waves, both before and after
PCI were also more often present in RCA related infarcts, as well as conduction
abnormalities. A non-diagnostic ECG (no ST elevation) was present in 18% in the
CX related infarcts versus 7% of the RCA related infarcts (p<0.001).  Success of
angioplasty was present in 91% and 89% respectively (p=NS). Outcome in CX related MI                                                                                               
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Table 2: Electrocardiographic and angiographic parameters
RCA CX P-value
Variable                                              (N=600)                        (N=229)                                    
Electrocardiographic Characteristics
No ST elevation 7% 18% <0.001
Cumulative ST elevation (mm)  8.7 ± 6.9 6.1 ± 5.1 <0.001
Cumulative ST deviation (mm) 14.7 ± 10.5 10.9 ± 9.71 <0.001
Q-wave pre angio 34% 19% <0.001
Q-wave post angio 65% 35% <0.001
AV block 16% 3% <0.001
Angiographic Characteristics
Multivessel disease 57% 60% NS
TIMI 3 pre-PCI 17% 16% NS
Collaterals
Rentrop 0 42% 73%
Rentrop 1 44% 22%
Rentrop 2,3 14% 5% <0.001
Post PCI TIMI 3 89% 91% NS
Therapy
PCI 97% 94%
CABG 1% 1.7%
Conservative 1.7% 4.4% NS
Quantitative Coronary Angiography after PCI (N=762)
Diameter Stenosis (%) 24 ± 13 24 ± 11 NS
Minimal lum.Diameter (mm) 2.5 ± 0.5 2.2 ± 0.5 <0.001
     Reference Diameter (mm)            3.2 ± 0.5 mm                2.8 ± 0.5 mm                <0.001
RCA = right coronary artery, CX = circumflex, AV block = atrioventricular block, 
PCI = primary coronary intervention, CABG = coronary artery bypass grafting 
Quantitative coronary angiography on the initial angiogram was performed in 762
patients (92%). The mean reference diameter of the CX was significantly smaller
as compared to the RCA. As the minimal luminal diameter was also significantly
smaller in the CX group, no difference in diameter stenosis was present after PCI
between the groups. 
Enzymatic infarct size and left ventricular ejection fraction was measured in 71%
and 82% of patients respectively. Enzymatic infarct size was significantly higher
and a strong trend towards a worse left ventricular ejection fraction was found in
patients with the CX as infarct related vessel. A poor left ventricular function,
defined as an ejection fraction less than 45% was more often present in the CX
related infarcts (37% vs. 26%, p<0.01). Mortality at 30 days and at one year was
significantly higher in the patients with the CX as infarct related vessel (Table 3).                                                                                                                                                            Chapter 3.2
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Table 3: Enzymatic Infarct Size, LVEF and Clinical Outcome
RCA CX P-value
Variable                                              (N=600)                        (N=229)                                    
LDHQ48 (N=588) 1.338 ± 1117 1.806 ± 1498 <0.001
Peak CK (IU/L) 1.821 ± 1735 2369 ± 1948 <0.001
Peak CK-MB (IU/I) 193 ± 162 250 ± 189 <0.001
LVEF (N=677) 49 ± 9 48 ± 9   0.07
LVEF<45% 26% 37% <0.01
30 day mortality 2.0% 4.8%   0.03
1 year mortality                                    3.7%                            7.0%                              0.04
RCA = right coronary artery, CX = circumflex, LDHQ48 = enzymatic infarct size assessed as
area under the LDH release curve during the first 48 hours after admission, LVEF = left
ventricular ejection fraction
We also compared the outcome only in 746 patents who did present with ST
elevation.  In this group of patients the outcome was also worse in CX compared
to RCA related MI (data not shown). 
The Kaplan Meier Survival curve, in which survival of the patients with LAD
related infarction is depicted as well, is shown in the Figure 1.
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Figure 1: Kaplan Meier survival in patients with CX versus RCA related acute myocardial
infarction.Outcome in CX related MI                                                                                               
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Discussion
This is the first study describing a comparison of outcome between CX and RCA
related acute myocardial infarction, in patients who are all treated with primary
angioplasty. It shows that enzymatic infarct size is larger and clinical outcome is
worse in CX related acute myocardial infarction despite less ECG abnormalities
on presentation. This study emphasizes that baseline ECG abnormalities may
underestimate final infarct size and outcome and therefore other diagnostic or risk
stratification tools should be used in these patients.
Previous studies have tried to stratify risk or distinguish the infarct related vessel
only based upon certain characteristics of the presenting ECG [8-10]. However, it
has often been stated that patients with right coronary artery related acute
myocardial infarction might have a worse outcome because of the higher
frequency of rhythm and conduction disturbances. The present study found the
opposite to be true and therefore re-emphasizes the value of identification of the
CX related infarcts based on the presenting ECG, or by using additional
diagnostic techniques such as posterior leads [11] or echocardiography to
document wall motion abnormalities as these patients are at high risk of adverse
events and patient management should be adjusted accordingly.
Explanation for worse outcome
There may be several explanation for the worse outcome of CX related MI.
Patients with CX related MI had less collaterals in our study. One may
hypothesize that a less well developed collateral circulation is related to the larger
infarct size. Elsman and co-workers found collateral circulation to be predictive of
infarct size and outcome [12]. On the other hand, angiographic assessment of
collateral circulation has its limitations: collaterals to the RCA may be detected
more easily (e.g. via the septal perforators) compared to collaterals to the
circumflex artery.  In addition, quantitative coronary angiography showed that the
vessel size diameter of the CX coronary artery was significantly smaller compared
to the RCA. Vessel diameter is an important predictor of outcome and this might
attribute to the worse outcome in the CX related infarcts as well [13,14].
Limitations
Enzymatic infarct size and left ventricular function were measured in 71% and
82% of patients respectively. However, the findings run parallel with clinical
outcome that could be assessed in 100% of patients. Furthermore no information
is available on the development of mitral regurgitation, which occurs frequently in
infarct patients with a CX related coronary artery. The final prognosis of CX
related acute myocardial infarction remains to be elucidated. A large proportion of                                                                                                                                                           Chapter 3.2
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patients who present as non ST elevation acute coronary syndromes show
significant enzyme rise during the first 24-48 hours of admission, without being
treated with reperfusion therapy. At angiography, often performed on the second
or third day after admission, these patients turn out to have an occluded CX
coronary artery [15,16]. The true prognosis of CX related myocardial infarction
therefore might only be assessed after the combination of both STEMI and non-
STEMI databases. 
Conclusion
This study shows that patients with acute myocardial infarction who undergo
primary angioplasty, in whom the CX is the infarct related vessel or culprit artery,
have a significantly larger infarct size and a worse clinical outcome, compared to
patients in whom the RCA is involved. This was seen despite fewer ECG
abnormalities on the presenting ECG. This emphasizes the fact that the 12-lead
ECG alone is often not enough for diagnosis and risk stratification of patients with
suspected acute myocardial infarction.Outcome in CX related MI                                                                                               
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Abstract 
Background
In patients with ST-segment elevation acute myocardial infarction (STEMI),
elevated cardiac troponin T (cTnT) on admission is associated with poorer
outcomes despite early reperfusion. Presentation delay is thought to the be most
important factor for the elevation of cTnT on admission. We evaluated
presentation delay and other potential predictors of elevated cTnT on admission
in patients treated with primary percutaneous coronary interventions (PCI) for
STEMI.
Methods
CTnT was measured upon arrival in the PCI centre in 444 patients with acute
STEMI. An elevated cTnT was defined as >
 0.05 µg/L.
Results
Mean age was 61.7 year and the patients were admitted after a median of 155
minutes after symptom onset. Almost 50% had an elevated cTnT on admission.
Patients with a positive cTnT on admission had less often successful primary PCI
(87% vs. 93%, p=0.048) and significantly higher rates of one year mortality (4.9%
vs. 1.3%, p=0.031). There was a significant association between presentation
delay and the prevalence of elevated admission cTnT, but even patients with
early presentation (<120 minutes after symptom onset) still had a high prevalence
of elevated cTnT (33%). After multivariate analysis, apart from presentation delay,
anterior myocardial infarction (MI) location and higher age were independent
predictors of elevated cTnT on admission.
Conclusion
In patients with STEMI, the prevalence of elevated cTnT on admission is high,
even in patients with early presentation. Independent predictors of elevated cTnT
on admission are presentation delay, increasing age and anterior MI infarction
location.                                                                                                                                                           Chapter 3.3
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Introduction
Several studies have demonstrated that an elevated cardiac troponin T (cTnT) on
admission in patients with ST-segment elevation myocardial infarction (STEMI),
predicts short- and long term mortality and failure of thrombolytic therapy or
primary percutaneous coronary interventions (PCI) [1-5].
 Giannitsis et al [6] found
that elevated cTnT on admission in STEMI predicts
 lower rates of post procedural
Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow, more severely
compromised myocardial perfusion despite normal epicardial flow and higher
rates of all cause and cardiac mortality. They also concluded that cTnT-positive
patients might require more aggressive adjunctive
  therapy when treated with
primary PCI. Although cTnT may be elevated even within 2 hours after symptom
onset [3,6],
  it is generally believed that cTnT elevations are mostly seen at a
minimum of 3-4 hours after the onset of chest pain [7].
Previous reports were hampered by relative small sample sizes and predictors of
elevated cTnT on admission are not yet clear. The present study was designed to
identify the independent predictors of elevated cTnT on admission in a large
population of STEMI patients treated with primary PCI and to study the
mechanism of cTnT elevation early after symptom onset.  
Patients and Methods
From June 2001 to November 2002, 507 consecutive patients
 were enrolled in the
On-TIME trial. Patients with STEMI, who were transferred to a PCI centre, were
randomised to early (pre-hospital) or late (in the catheterization laboratory)
initiation of tirofiban. Inclusion and exclusion criteria have been described
previously [8].
 In brief: patients with chest pain of > 30 minutes' duration and ECG
changes with ST segment elevation > 2 mm in the precordial leads or >1 mm in
the limb leads in at least 2 contiguous leads were included in the study. The
ability to perform PCI within 6 hours after symptom onset was also an enrolment
criterion. The exclusion criteria were age over 80 years, women less than 50
years of age, patients who were treated with thrombolytic therapy in the previous
24 hours, patients on warfarin or acenocoumarol within the last 7 days and
patients with a contraindication to glycoprotein IIb/IIIa blockade. Patients with
severe heart failure or cardiogenic shock and patients who were on hemodialysis
were also excluded.
Each institution’s Review Board or Ethical Committee approved this study. All
patients gave written informed
 consent. The study population consisted of 444
patients (88%), by whom cTnT was measured on admission. Patients were
stratified into cTnT-positive and cTnT-negative. Baseline characteristics,Predictors of elevated cardiac troponin T
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angiographic parameters and clinical outcome were compared between the cTnT-
positive and cTnT-negative patients. 
Presentation delay was defined as the time from symptom onset
  to infarct
diagnosis (first ECG). Ischemic time was defined as time from symptom onset to
first
 balloon inflation.
 
Serum marker analyses 
CTnT levels were measured by using a point-of-care system (Cardiac reader,
Roche Diagnostics, Almere, Netherlands). CTnT >
 0.05 µg/L
 was considered as
positive. Creatine kinase (CK), creatine kinase MB (CK-MB) activity and
cumulative Lactate Dehydrogenase ( LDHQ48) concentrations were analysed with
the Elecsys 2010 system (Roche Diagnostics). Glucose was measured by a
hexokinase method using a Modular PPE module device (Roche Analytics,
Almere, Netherlands). High sensitivity C-reactive protein  (HsCRP) was measured
by immunochemical analyses of HsCRP (Modular, Roche, Almere, Netherlands)
and the White blood cell count (WBC) is determined on the Sysmex XE 2100
(Goffin Meyvis, Etten-Leur, Netherlands).
To evaluate the relation between symptom onset to admission time and elevating
cTnT, we stratified the patients according to presentation delay in an early group
who presented within 120 min after the onset of symptoms, an intermediate
group, who presented between 120 and 180 minutes and a late group who
presented later than 180 minutes. 
Angiographic data analysis
All angiograms were analyzed by an independent core lab (Diagram B.V., Zwolle,
The Netherlands) who were blinded to all data. Apart from the coronary
angiogram; TIMI flow grades and myocardial blush grade (MBG) were assessed
after the angioplasty procedure, as previously described [9,10]. Residual stenosis
was assessed visually. Procedural success was defined as postprocedural TIMI 3
flow of the infarct related vessel (IRV) and residual stenosis less than 50%. Left
ventricle ejection fraction (LVEF) was assessed angiographically.
ST-segment resolution
For assessment of ST-segment resolution, serial 12-lead ECG
 recordings just
before PCI and immediately after return to the
 coronary care unit were analysed
by the same core lab blinded to
 the clinical data. ECG’s with bundle-branch block,
pacemaker
 rhythm, or incomplete or poorly interpretable ECG recordings
 were not
included in this analysis. The ST segment in the lead showing maximal deviation                                                                                                                                                           Chapter 3.3
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was measured 60 ms after the J point. The resolution of the ST
 segment was
calculated in relative reductions from baseline expressed as percentage.
 
Follow-up
Records of included patients who visited our outpatient clinic were reviewed. For
all other patients, information was obtained from the patient's general physician or
by direct telephone interview with the patient. For patients who died during follow-
up, hospital records and necropsy data were reviewed. Patients were followed up
prospectively for one year
  by use of hospital records, questionnaire, and
telephone contact.
 
Statistical analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean or median and 25-75 percentile
and categorical data as percentage, unless otherwise denoted. The analysis of
variance and the chi-square test were appropriately used for continuous and
categorical variables respectively. A multivariate logistic regression analysis was
performed to identify independent predictors of high troponin level at admission.
Significant variables analyzed are reported with their respective odd ratios and
95% confidence intervals. For all analyses, statistical significance was assumed
when the two tailed probability value was < 0.05. 
Results
Baseline 
CTnT on admission was measured in 444 patients. Mean age of these patients
was 61.7 years and they were admitted after a median of 155 minutes after
symptom onset. Almost 50% of the patients had an elevated cTnT on admission. 
Clinical characteristics of the study group stratified
  by admission cTnT are
displayed in Table 1. Patients with elevated cTnT on admission were significantly
older, more often female, had more often a heart rate >100 bpm or an anterior
myocardial infarct location. Presentation delay (median 106 vs. 80 min.) was
longer and Killip class > 1 was significantly more often present in the cTnT
positive patients. Admission CK and CK-MB were significantly higher in the cTnT
positive patients. WBC was comparable in both groups but Hs CRP was
significantly higher in the cTnT positive patients. Prevalence of elevated
admission cTnT was 33% in the early, 46% in the intermediate and 62% in the
group with long presentation delay (Figure 1). Prevalence of increased cTnT wasPredictors of elevated cardiac troponin T
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54% in the early Tirofiban group, compared to 46% in the late Tirofiban group (p =
0.06). 
Table 1: General Characteristics                                                                     
cTnT-positive cTnT-negative p-value
Variable                                              (n=208, 47%)              (n=236, 53%)                          
Age (years ± SD) 64 ± 11       60 ± 10 < 0.001
Female Gender n, (%)  49 (24)          37 (16)  0.04
Diabetes mellitus, n (%) 26 (13)       18 (8)  0.09
Hypertension, n (%) 60 (29) 64 (27)  0.7
Hyperlipidemia, n (%) 42 (20) 61 (26)  0.2
Smoking, n (%) 128 (62) 150 (65)  0.5
Heart rate >100 bpm, n (%) 26 (13)                  8 (4) < 0.001
Previous MI, n (%) 14 (7)  25 (11)        0.2
Previous PCI, n (%) 7 (3) 17 (7)          0.08
Previous CABG, n (%) 3 (1) 8 (3) 0.2
Anterior infarction, n (%)  115 (57)         75 (34) < 0.001
Presentation delay (min) 106 (63-182) 80 (50-128) < 0.001
Median (25-75 percentiel)
Killip class>1, n (%) 42 (22) 23 (11)  0.003 
Glucose (± SD) 9.92 (3.77) 9.46 (2.58)  0.1
CK on admission U/L 190 (125-348) 98 (70-148)             < 0.001
CK peak U/L, 1879 (804-3889) 1489 (661-3027)    0.007
CK-MB on admission U/L 21 (14-38) 12 (9-15)            < 0.001
CK-MB peak U/L 229 (89-425) 189 (76-307)            < 0.001
LDHQ48 1419 (439-2838) 1093 (441-2119) 0.10
WBC 10
9/L 11.8 ± 3.5 11.9 ± 3.6 0.8
Hs CRP, mg/L  3.1 (1.4-6.0) 2.3 (1.3-4.5) 0.02
Early tirofiban initiation, n (%) 112 (54) 106 (45) 0.06
Cum. ST-elevation (mm) (± SD) 11 ± 8 9.5 ± 7 0.07
ST resolution, % (± SD)                     73 ± 29                         74 ± 39                         0.9       
Values given as means with SD in parentheses or as absolute numbers with relative
frequencies. Values of CK, Ck-MB, LDHQ48 and Hs CRP are given as median and 25-75
Percentile. MI = myocardial infarction, CABG = coronary artery bypass grafting, PCI =
primary coronary intervention. CK= creatine kinase , CK-MB = creatine kinase MB mass,
LDHQ48 = Enzymatic infarct size (area under the lactate dehydrogenase release over 48h
curve). Hs CRP = high-sensitive C-reactive protein.                                                                                                                                                           Chapter 3.3
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Angiographic findings
Multivessel disease and thrombus load were comparable in cTnT positive- and
cTnT negative patients (56% vs. 54% and 31% vs. 27%, respectively) (Table 2).
Pre PCI TIMI 3 and TIMI 2,3 were significantly higher in the cTnT positive patients
(21% vs. 13%, p =0.03 and 45% vs. 32%, p= 0.008, respectively). Both post PCI
TIMI 3 flow and MBG 3 were significantly lower in the cTnT positive patients (87%
vs. 93%, p =0.048 and 42% vs. 63%, p  < 0.001, respectively). LVEF was
significantly lower in the cTnT positive patients.
Table 2:  Angiograpic parameters pre- and post PCI.
          cTnT- Positive      cTnT negative          p-value
Variable                                              (n=208, 47%)                    (n=236, 53%)                                      
Pre-PCI
Multivessel Disease, n (%) 115 (56) 122 (54) 0.7
TIMI 3 43 (21) 29 (13) 0.03
TIMI 2,3 92 (45) 72 (32) 0.008
Thrombus 63 (31) 60 (27) 0.4
Post-PCI 
TIMI 3  161 (87) 197 (93) 0.048
MGB 3 78 (42) 132 (63)          <0.001
Coronary stenting, n (%) 127 (69) 153 (74) 0.3
LVEF                                                   42 ± 12                                     47 ± 9                       <0.001
TIMI = thrombolysis in myocardial infarction, MBG = myocardial blush grade, LVEF = left
ventricle ejection fraction.
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Figure 1: Prevalence of elevated cTnT on admission according to time from symptom onset to
admission.Predictors of elevated cardiac troponin T
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Infarct size and outcome
LDHQ48 and cumulative ST- segment elevation tended to be higher in the cTnT
positive patients. No significant difference was found in ST segment resolution
between cTnT positive and cTnT negative patients (Table 1). 
At 30 days, cardiac and all-cause mortality tended to be higher in the cTnT
positive patients. At one year, cardiac death (3.4% vs. 0.4%, p = 0.03) and all-
cause mortality (4.9% vs. 1.3% p = 0.03) were significantly higher in cTnT positive
patients. Rates of combined reinfarction and/or death were not statistically
different in both groups (Figure 2). 
Figure 2: Short- and long-term outcomes. At 30 days rates of cardiac death and all causes
of mortality were not significantly different between both groups. However at one year rates
of cardiac death and all causes of mortality were significantly higher in the cTnT positive
patients.
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Multivariate analysis
To assess the independent predictors of an elevated cTnT on admission, we
performed a multivariate analysis and included age, gender, infarct location, Killip
class, diabetes, previous PCI, heart rate>100 bpm, Hs CRP and presentation
delay. Age (years), Hs CRP (mg/ml) and presentation delay (minutes) were
included as continuous variables. Multivariate analysis revealed that age, (OR
1.03; 95%CI: 1.01-1.06, p= 0.01), anterior myocardial infarction (OR 2.98; 95%CI:
1.78-4.99, p= <0.001) and presentation delay per 30 minutes (OR 1.23; 95%CI:
1.10-1.34, p =<0.001) were independent predictors of an elevated cTnT on
admission (Table 3).
Table 3: Predictors of Troponin T elevation multivariate analysis
Variable                                              OR                    95% CI                        P          
Age (per year) 1.03 1.01-1.06 0.01
Anterior infarction 2.98 1.78-4.99 < 0.001
Presentation Delay (per 30 min.) 1.23 1.10-1.34 < 0.001
Diabetes 0.64 0.25-1.06 0.3
Previous PCI 0.31 0.09-1.05 0.06
Female gender 1.41 0.72-2.76 0.3
Heart rate >100 bpm 4.74 0.81-27.6 0.08
Killip class>1   1.86 0.72-4.76 0.2
Hs CRP (per mg/L)                              1.01                 0.99-1.40                    0.2       
Hs CRP = high-sensitive C-reactive protein
Discussion
This study demonstrates that apart from presentation delay, anterior myocardial
infarct location and higher age are also independent predictors of elevated
cardiac troponin T on admission. Elevated cTnT on admission is associated with
worse angiographic and clinical outcome, despite primary PCI and treatment with
tirofiban. 
Predictors of elevated cTnT on admission 
Our data show that in patients with STEMI, cTnT identifies a high risk group,
characterized by Killip class > 1, elderly and patients with anterior myocardial
infarct location. A previous study [7] emphasized that troponin T elevations are
only seen at a minimum 3-4 hours after the onset of symptoms. Other studies,
however, reported an elevated TnT on admission even within 2 hours after
symptom onset [3,6].
We consistently found that admission delay was associated with elevated
troponin on admission [6].
  Nevertheless,
  almost 50% of the patients had anPredictors of elevated cardiac troponin T
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elevated cTnT on admission, whereas even patients with short presentation delay
(<120 minutes after symptom onset) had a relatively high prevalence of elevated
cTnT (33%). Why patients with short symptom duration would have an elevated
cTnT on admission is not yet clear. In these patients the onset of symptom may
have gone undetected and thus the true onset of the infarction could have begun
much earlier. They could have had a previous silent event that caused cTnT
release [3]. Previous study reported that acute coronary occlusion in STEMI, is
often the final stage in a series of successive events that occurred in the
preceding days or weeks [11].
 Other possible explanation of elevated cTnT short
after symptom onset is a large area at risk, cTnT positive patients had higher
levels of peak CK-MB and lower LVEF (Table 1, Table 2). Furthermore the
absence of collaterals may also explain the elevated troponin on admission.
Matetzky et al found that patients with elevated troponin have less frequently
collateral blood flow [5].
 In addition, in the current study patients with elevated
cTnT on admission more often had a Killip class>1 and we previously reported
that a Killip class > 1 is associated with worse outcome in STEMI patients [12].
 
Prognostic value
Previous studies have demonstrated that both thrombolysis and primary PCI
therapy are less effective in cTnT positive patients [2,4,5,13].
 Others have found
that epicardial flow (TIMI flow
 < 3) remained more frequently compromised and
myocardial
  reperfusion (as measured by serum cardiac markers) was more
impaired in cTnT-positive than in cTnT-negative patients [6]. 
Our data confirm that elevated cTnT is associated with impaired myocardial
perfusion, as measured by MBG, and lower rates of post-PCI epicardial TIMI 3
flow. Previous studies [14,15] showed that pre-procedural patency (TIMI 2 or 3) is
associated with favorable outcome. In our study we found that outcome was
worse in cTnT positive patients, although these patients had higher initial patency
rate of the infarct related vessel (IRV). This may be caused by early washout of
cardiac enzymes in patients who presented with open IRV (Table 2). In addition,
the higher rates of TIMI 3 flow in cTnT positive patients could also be explained
by the higher rates of anterior myocardial infarct location (Table 1), since it has
been found that patients with an anterior myocardial infarct location more often
have a patent IRV than non anterior infarct location [16]
 In addition, our study
confirms the results of a previous study [17] that found an inverse relation
between LVEF and cTnT. Furthermore, our results are consistent with Kurowski
et al, who found a poorer outcome in patients with elevated troponin as compared
to patients with normal troponin values on admission [18].                                                                                                                                                           Chapter 3.3
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Implication for treatment
Because elevated cTnT on admission have a worse prognosis, efforts should be
made to improve their treatment. Although in a general population with STEMI
treated with primary PCI and coronary stenting, glycoprotein IIb/IIIa inhibitors
have limited value [19],
 in patients with elevated cTnT on admission there may be
more clear effects. 
Limitations
This study is a post-hoc, observational analysis and the results were obtained in
patients who underwent primary PCI and may not relate to patients treated with
thrombolytic therapy. Second, troponin T was measured using a point-of-care
reader allowing only identifying patients with troponin levels above 0.05 µg/L.
However, by definition, patients with levels above 0.03 µg/L are classified as non-
STEMI and increased risk has been reported by the TACTICS TIMI 18 Study
Group even at levels close to the lower detection limit [20]. Thus, it is likely that
the On-Time study has underestimated the true proportion and risk in this subset.
Nevertheless, studies using higher cut-off values found similar results [3,6].
Another limitation is that we measured CK-MB activity and not CK-MB mass,
however, CK-MB mass is more sensitive and more specific. 
Conclusion
This study shows a high prevalence of elevated cardiac troponin T on admission 
in patients with STEMI treated with primary PCI, even in patients who presented
early after symptom onset. Apart from presentation delay, increasing age and
anterior infarct location are also independent predictors of elevated cTnT on
admission. Predictors of elevated cardiac troponin T
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Abstract
Objective
To review the currently available data to investigate the clinical benefit of high-
and low-dose glucose-insulin-potassium (GIK) in patients with ST segment
elevation acute myocardial infarction (STEMI).  
Design
Quantitative analysis of all randomised trials on GIK in patients with STEMI.
Electronic and manual searches for RCT of GIK in STEMI were performed, with
regard to inclusion criteria, dose of GIK and additional use of reperfusion therapy
and a meta-analysis with the primary end-point 30-day mortality was performed.
Patients
Data of sixteen randomised trials, involving 26,273 patients, were included.
Results
Studies were conducted between 1962 and 2005. Overall, hospital mortality was
9.6% after GIK compared to 10.2% in controls (p=0.088). GIK infusion was not
associated with an increase in major adverse events.
Conclusion
This quantitative analysis of GIK in patients with STEMI did not show a beneficial
or detrimental effect of GIK infusion on 30-day mortality. GIK infusion should not
be part of the standard therapy for patients with STEMI.                                                                                                                                                            Chapter 4.1
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Introduction
Since the early 1960s potential benefits of glucose-insulin-potassium (GIK) for ST
segment elevation acute myocardial infarction (STEMI) have been studied [1-3].
Potential mechanisms of action
During the acute phase of myocardial infarction insulin levels are low while
cortisol and glucagon levels are increased [4]. This is associated with decreased
insulin sensitivity, resulting in impaired glucose utilisation and an increased
turnover of free fatty acids (FFA) [5]. Although FFA are the primary energy source
for non-ischemic myocardium, myocardium can use various forms of energy
substrates, including glucose [6]. Increased circulating FFA levels and reduced
insulin sensitivity may limit cellular uptake of glucose and promotes the use of
FFA [7]. FFA may have a detrimental effect on ischemic myocardium through
varying pathways. Energy supply by FFA is associated with relatively high oxygen
consumption in comparison to the utilisation of glucose [8].
 Moreover, in contrast
to glucose, FFA can not be metabolised anaerobically. Furthermore, excess FFA
metabolism increases susceptibility to ventricular arrhythmias and reperfusion
injury due to disturbances in calcium homeostasis and accumulation of free
radicals [9,10].
Administration of GIK lowers circulating levels of FFA by inhibitory effects of
insulin on lipolysis [11]. This decrease in FFA levels, in combination with an
increase in glucose and insulin availability, promotes the myocardial use of
glucose over FFA [9]. Glucose is less oxygen consuming and may have beneficial
effect on the preservation of mechanical function and membrane stability [12].
GIK may also reduce arrhythmias after successful reperfusion [13]. 
As insulin itself induces coronary vasodilatation, myocardial metabolism could
further be improved through enhanced myocardial perfusion [14-16].
  Finally,
intensive insulin therapy may normalize glucose levels, which has been shown to
be beneficial in critically ill patients [17].
A meta-analysis of the older randomised trials of GIK in patients with STEMI,
suggested beneficial effects of GIK, but studies in the reperfusion era were
lacking [18].
  Since then, several additional clinical trials have been performed
[5,19-30].
 The more recent trials did not show benefits of GIK [19,20].
We designed this quantitative analysis to review the currently available data to
investigate the clinical benefit of high- and low dose GIK in patients with STEMI.  Glucose-Insulin-Potassium in STEMI                                                                              
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Methods
We attempted to obtain results from all completed, published, randomised trials of
GIK in STEMI. The literature was scanned by formal searches of electronic
databases (MEDLINE, PubMed) and informal searches for studies concerning the
potential mechanism of action of GIK. Since it has been suggested that high dose
GIK is superior to low dose GIK [25], we performed stratified analyses of the
effects of low and high dose of GIK. High dose GIK was defined as an
intravenous infusion of GIK in a dose equal to or higher than used by Rogers et
al, 30% glucose (300 mg/L), 50 IU/L regular insulin and 80 mmol/L potassium
chloride at 1.5 mL/kg per hour infusion rate (approximately 5 units insulin/hour)
[23]. Our primary efficacy outcome of interest was 30-day mortality. We calculated
the odds ratio (OR) for 30-day/hospital mortality of patients treated with GIK as
compared to those treated with placebo or control. The OR and its 95%
confidence interval (CI) were calculated for each trial and the (grand) totals.
Results 
A total of 16 randomised clinical trials
 were identified and included in this meta-
analysis [2,3,11,19-31].
 Studies were conducted between 1962 and 2005. The
total number of patients was 26,273 and the overall 30-day mortality of the whole
population was 2,603. Baseline characteristics of all randomised trials are
summarised in Table 1. Numbers of enrolled patients and hospital/30-day
mortality rates are summarised in Table 2.
The studies used GIK in different doses, and the time from onset of symptoms of
myocardial infarction to treatment varied, with a large proportion of patients being
treated more than 6 hours after onset of symptoms. The first randomised
prospective trial in the era of reperfusion, the DIGAMI study, including only
patients with hyperglycaemia on admission, found that the combination of insulin-
glucose infusion with an intensive insulin treatment for at least three months after
discharge reduced one-year mortality (19% vs. 26%, p<0.05) [5]. In DIGAMI,
approximately 50% of the patients were treated with reperfusion therapy. The
Estudios Cardiologicos LatinoAmerica (ECLA) pilot trial showed a trend towards a
beneficial effect of GIK,
 particularly in patients who received reperfusion therapy
(62%, n = 252) [25].                                                                                                                                                           Chapter 4.1
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Table 1: GIK trials and GIK doses used in acute myocardial infarction
Study          Publication Patients     Glucose Insulin     Infusion rate   Infusion period
                            Year            (n=)                (%)         (IU/L)      (mL/kg/h)                 (h)        
High dose GIK
DIGAMI[11] 1995 620 5 80 1.5 l/24h 24
GIPS-II[19] 2005 889 20 variable 2 12
ECLA II[20] 2005 20201 25 50 1.5 24
Heng[21] 1977 27 50 21 1.5 6-12 (11)
Stanley[22] 1978 110 30 50 1.5 48
Rogers[23] 1979 134 30 50 1.5 48
Satler[24] 1987 17 30 50 1.5       48
ECLA-I[25] 1998 135 25 50 1.5 24
GIPS-I[26] 2003 940 20 50 3 12
REVIVAL [31]   2004 312 20 40 1.8 24
Low dose GIK
Pentecost [2] 1968 200 10 30 1.5//24h 48
MRC*[3] 1968 968 16 10x2 -          14 days
ECLA-I[25] 1998 133 10 20 1.0 24
Mittra*[27] 1965 170 24 10x2 -         14 days
Pilcher*[28] 1967 102 24 10x2 -         14 days
Hjermann*[29] 1971 204 20 16 -        10 days
Pol-GIK [30]          1999           954                  10        20                    0.6                   24        
 *glucose, potassium oral; insulin subcutaneous
Hospital-mortality in patients treated with reperfusion therapy was 5% in patients
treated with GIK versus 15% in controls (p<0.01), whereas no effect of GIK was
observed in patients not treated with reperfusion therapy (9% vs. 7%). The Polish-
Glucose-Insulin-Potassium (Pol-GIK) trial included 954 patients, of which 60%
were treated with reperfusion therapy. Patients with diabetes on insulin therapy
were excluded.Total mortality at 35 days was even higher in the GIK group (8.9%)
than in controls (4.8%, p<0.01) [30]. However, in this trial low-dose GIK was used.
The REVIVAL study showed that GIK improves myocardial salvage only among
diabetic patients. However, 30-day and 6 month mortality was not affected by GIK
[31]. The Glucose Insulin Potassium Study-I (GIPS-I), included 940 STEMI
patients treated with primary angioplasty. High-dose GIK resulted in a non-
significant reduction of mortality (4.8% vs. 5.8%, p=0.50) with a significant
mortality reduction in patients without signs of heart failure on admission (1.2%
vs. 4.2%, p=0.01) [26].Glucose-Insulin-Potassium in STEMI                                                                              
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Table 2: Hospital mortality in high dose and low dose GIK versus control
Included patients Hospital/30-days mortality
Study  GIK  Control  GIK     Control P- value
                                 N            N                          N (%)                   N (%)                             
High dose GIK 
Heng 12 15 1 (8)        0 (0) 0.26
Stanley 55 55 4 (7)       9 (16) 0.14
Rogers 61 73 4 (7)        9 (12) 0.26
Satler 10 7 0 (0)        0 (0) 1.0
GIPS 476 464 23 (5) 27(6) 0.5
ECLA 135 139 10 (7)       16 (12) 0.10
DIGAMI    306       314                   28 (9)          35 (11) 0.4
REVIVAL 155 157 7(4.5)       5(3.2) 0.54
ECLA II 10091 10110 976 (9.7)    1004 (10.0) 0.45
GIPS II 444 445 13 (2.9)       8(1.8) 0.26
Total (High dose) 11,745 11,797 1,066 (9.1)    1,113 (9.4) 0.3
Low dose GIK
Mittra 85 85 10 (12)        24 (28) 0.007
Pilcher 49 53 6 (12)        12 (23) 0.17
Pentecost 100 100 15 (15)        16 (16) 0.85
MRC 480 488 103 (21)       115 (24) 0.43
Hjermann 104 100 11(11)        20(20) 0.06
ECLA 133 139 10 (8)        16 (12) 0.26
Pol-GIK 494 460 44 (9)        22 (5) 0.012
Total (Low dose) 1445 1425               199 (13.8)  225 (15.8) 0.13
Total (All dose)        13,190     13,083              1,265 (9.6)            1,338 (10.2)        0.088
The largest published trial (ECLA–II) randomised 20,201 patients to 24-hours of
high dose GIK or control in adjunct to reperfusion therapy [20]. There was no
difference in 30-day mortality between patients treated with GIK and the control
group (10.0% vs. 9.7%, p=0.45). There was a weak trend for a beneficial effect of
GIK in patients who were treated with a primary percutaneous coronary
intervention (PCI), 57/906 (6.3%) in the control group vs. 44/925 (4.8%) in the
GIK group (p=0.26). The latest trial, the Glucose Insulin Potassium Study-II
(GIPS-II), was terminated early according to the interim analysis, as statistically
significance was unlikely to be reached on further inclusion [19]. The trial included
889 patients with STEMI, randomised to either GIK therapy for a period of 12
hours or no infusion. Thirty-day mortality was slightly, but not significantly, higher
in patients who received GIK therapy, 2.9% versus 1.8% (p=0.26).                                                                                                                                                           Chapter 4.1
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Meta-analysis
Overall, GIK did not reduce hospital mortality (9.6% vs. 10.2%, RR 1.0; 94%CI:
0.87-1.01, p=0.088) (Figure 1). The stratified analysis according to GIK-dose,
including all randomised trials investigating the influence of GIK on 30-day or in-
hospital mortality, showed that neither administration of high dose (9.1% vs.
9.5%, RR 0.96; 95%CI: 0.89-1.04, p=0.35) nor low dose GIK (13.8% vs. 15.8%,
RR 0.87; 95%CI: 0.73-1.04, p=0.14) resulted in a significant reduction of hospital
mortality. 
Adverse effects
The reported adverse effects of GIK treatment were mild. Withdrawal because of
side effects was rare. Significant phlebitis (at the site
 of infusion) was frequent in
the GIK infusion group (3.4%) compared with the control group (0.2%;
 p< 001)
[20]. Other studies demonstrated a small increase of signs of congestive heart
failure after GIK [25]. In the DIGAMI study, 15% of the patients who received
intensified therapy had a hypoglycaemic event, compared to none in the control
group [5]. In the ECLA II study, symptomatic hypoglycaemia although rare,
occurred more often in the GIK group (0.1% in controls versus 0.4% in the GIK
patients) [20]. In the Pol-GIK trial, hypoglycaemia occurred in 8% of the patients
treated with GIK [30]. They reported hyperglycaemia in less than 1% with no
differences between GIK and control group. With a blood glucose level > 16.8
mmol/L as criteria to stop the infusion, only 1% was interrupted. Hjermann used a
reduced dose of insulin, which prevented the occurrence of hypoglycaemia [29]. 
Discussion
This large meta-analysis of GIK involving 26,273 patients with STEMI did not
show beneficial effects of GIK infusion on 30-day mortality. 
Comparison to previous meta-analysis
The results of our meta-analysis differ from the previous meta-analysis as
performed by Fath-Ordoubadi and Beatt in which a beneficial effect of GIK was
suggested [18]. In this meta- analysis a total of 1932 patients were included.
Hospital
 mortality was reduced from 21% in the placebo
 group to 16.1% in the GIK
group (p=0.004; odds ratio,
 0.72; 95% CI 0.57-0.90). Our meta-analysis included
all more recent trials
  which failed to show significant beneficial effect of GIK
[19,20].
 This may be due to methodological differences between the older clinical
trials and the recent trials. Furthermore, treatment of STEMI has changed and
clinical outcome of these patients has been improved. Compared to our meta-
analysis, the meta-analysis performed by Fath-Ordoubadi and Beatt, showed
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higher mortality in both control (21.0% versus 10.2%) and GIK patients (16.1%
versus 9.7%) [18]. This may be due to the more frequent use of reperfusion
therapy as well as beta blockers, ACE inhibitors and statins in the more recent
trials. In addition, the beneficial effects of GIK may have been overshadowed by
improvement in the general management of STEMI.
GIK and time to reperfusion
It has been proposed that
 glucose-insulin therapy may delay ischemic necrosis to
some degree before reperfusion, thus lengthening
  the period during which
effective myocardial salvage is possible
  with reperfusion strategies [32]. Time
between admission and initiation of GIK varied among the studies. Mittra
mentioned 10 hours, whereas in the MRC study 70% of patients were treated
within 30 minutes after inclusion [27,3]. In the ECLA study, time from onset of
symptoms until the initiation of GIK treatment was 10 to 11 hours [25]. Whether
the clinical effects of GIK on outcome are influenced by the time of initiation of
treatment is not known. Reperfusion is mandatory as prolonged severe ischemia
even in the presence of GIK, will eventually result in necrosis. It has been
postulated that GIK infusion would be most effective when initiated before
reperfusion, with continuation of the infusion for several hours after reperfusion
[33].
Future of GIK in myocardial infarction
The controversial results of the trials with GIK may have several reasons. The
older trials had well known limitations with low patient numbers, poor design and
methodological discrepancies. The more recent trials were larger, had a better
design and in most trials GIK infusion was added to reperfusion therapy.
However, even in the more recent trials, the metabolic effects of administration of
GIK may have been not optimal. GIK infusion was started just a short time before
reperfusion therapy and significant hyperglycaemia was induced in a large
population of patients. Additional studies may be needed to find out whether GIK
is effective when given early after symptom onset, for instance during
transportation to hospital [34]. Intensive insulin therapy to maintain blood glucose
with a more optimal range reduces morbidity and mortality among critically ill
patients in the surgical intensive care unit [17].
 However, although the results of
DIGAMI-1 were promising, the results of DIGAMI-2 did not confirm the benefits of
intensive insulin treatment in type 2 diabetic patients with STEMI [35].                                                                                                                                                            Chapter 4.1
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Conclusion
This large meta-analysis, involving 26,082 patients, of GIK therapy in patients
with STEMI, did not show a beneficial or detrimental effect of GIK infusion on 30-
day mortality. Therefore, GIK therapy in the current form should not be applied in
patients with STEMI. Glucose-Insulin-Potassium in STEMI                                                                              
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Abstract
Background 
There are conflicting data concerning the effect of treatment with Glucose-Insulin-
Potassium (GIK) in ST segment elevation myocardial infarction (STEMI). Early
studies showed beneficial effects of GIK, however, recent large sample size trials
did not confirm this, or suggested only benefits in patients without heart failure.
We aimed to evaluate long term effects of GIK in patients with STEMI without
signs of heart failure, all treated with reperfusion therapy.
Methods 
From August 2003 to December 2004, 889 STEMI patients without signs of heart
failure were randomized to standard care (N= 444) or additional GIK infusion (N=
445). Glucose-potassium (20% glucose with 80 mmol potassium/L) was infused
at 2 ml/kg body weight per hour for 12 hours through a peripheral line. Short-
acting insulin was started according to admission glucose and adjusted based on
hourly measured glucose. Clinical end-points were number of death, reinfarction
and re-vascularisation at one year. 
Results
One year follow up was available in 864 patients (97.2%), 432 in the GIK group
and 432 in the control group. Mortality rate was 5.3% in GIK and 3.9% in control
patients, p = 0.33.  Rates of reinfarction and revascularization were 4.6% vs.
4.6% and 15.5% vs. 15.0%, in GIK versus control patients.
Conclusion
In patients with  STEMI without signs of heart failure treated with reperfusion
therapy, GIK therapy offers no clinical benefit at one year.                                                                                                                                                            Chapter 4.2
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Introduction
There are conflicting data concerning the effects of Glucose-Insulin-Potassium
(GIK) in the treatment of ST segment elevation myocardial infarction (STEMI).
The meta-analysis of Fath-Ordoubadi and Beatt showed a benefit of GIK infusion
[1].
  However, studies included in this meta-analysis often had a small sample
size, were of older date and none of the patients received reperfusion therapy.
The DIGAMI-I study found that the combination of insulin-glucose infusion with an
intensive insulin treatment resulted in a reduction in one-year mortality from 26%
to 19%, p<0.05 [2].
  The
  Glucose-insulin-potassium study-I (GIPS–I) showed
clinical benefit of GIK in STEMI patients without signs of heart failure [3], but the
GIPS-II could not confirm this finding [4]. Two other recent large sample size
trials, CREATE-ECLA– II and DIGAMI-II [5,6], showed no beneficial effects of
GIK.
However, the long term effect of GIK in patients with STEMI without signs of heart
failure treated with reperfusion is not yet clear. Hence we assessed clinical
outcome at one year follow up in patients enrolled in the GIPS-II study.  
Methods
The design and short term results of the GIPS-II study have been described in
detail [4,7].
 In brief, from August 2003 to December 2004, 889 consecutive STEMI
patients without signs of heart failure on admission were randomized to traditional
care (N= 444) or additional GIK infusion (N= 445). Glucose-potassium (20%
glucose with 80 mmol potassium/l) was infused at 2 ml/kg body weight per hour
for 12 h through a peripheral line. Short-acting insulin was started according to
admission glucose and adjusted on the basis of hourly measured glucose. STEMI
was defined as chest pain suggestive for myocardial ischemia for at least 30
minutes, time from symptom onset to hospital admission <6 hours, and an ECG
with ST-T segment elevation of >1 mV in 2 or more leads. Patients had to be
eligible for either thrombolysis or primary PCI. Patients with signs of heart failure
at admission (Killip class ≥2) were excluded. Heart failure at admission was
defined as the existence of either one of the following symptoms, that is, a heart
rate over 90 beats/min, a systolic blood pressure beneath 100 mmHg with
anterior myocardial infarction, a third heart sound, or rales, more than one hand
wide. Further exclusion criteria were unwillingness to participate and/or the
existence of a life-threatening disease with a life expectancy of <6 months. There
was no upper age limit. The patients were randomly assigned to high-dose GIKOne-year outcome of GIPS-II                                                                                           
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infusion or no infusion (ratio 1:1). Randomization and GIK administration took
place in the hospital that initiated the reperfusion therapy. 
End points 
The primary end point was 30-day mortality. Secondary end points were 1-year
mortality, reinfarction and revascularisation. 
Follow-up
Records of included patients who visited our outpatient clinic were reviewed. For
all other patients, information was obtained from the patient's general physician or
by direct telephone interview with the patient. For patients who died during follow-
up, hospital records and necropsy data were reviewed. Patients were followed up
prospectively for one year
  by use of hospital records, questionnaire, and
telephone contact.
 
Statistical analysis 
Statistical analysis was performed with the Statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA) version 12.0.1. Continuous data were
expressed as mean ± standard deviation of mean and categorical data as
percentage, unless otherwise denoted. The analysis of variance and the chi-
square test were appropriately used for continuous and categorical variables
respectively. Survival analysis was assessed by using Kaplan Meier method and
difference in survival was assessed by log-rank test. Significant variables
analyzed are reported with their respective odd ratios and 95% confidence
intervals. For all analyses, statistical significance was assumed when the two
tailed probability value was < 0.05. 
Results
One year follow-up was available in 864 patients (97.2%). The flow chart of GIPS-
II study is shown in figure 1. Baseline characteristics and treatment of the study
population are displayed in table 1.                                                                                                                                                           Chapter 4.2
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Figure 1: GIPS-II study flow chart
Clinical outcomes at one year
At one year 25 patients (2.8%) were lost to follow-up; 12 in the GIK group and 13
in the control group. The incidence of mortality was not significantly different
among patients treated with GIK and the control group, 5.3% vs. 3.9%, p =0.33
respectively. Figure 2 shows the Kaplan Meier survival curves. Rates of recurrent
myocardial infarction were identical among patients treated with GIK and control
patients, 4.6% in each, p= 0.99. Rates of repeat intervention were also similar,
15.5% in the GIK group and 15.0% in the control group, p= 0.85. Coronary artery
bypass grafting was performed in 9.7% and 8.6%, p= 0.56 in the GIK and control
group, respectively. Rates of cerebrovasculair accident were identical: 1.2% in
both groups. The incidence of mortality was slightly higher in the GIK group as
compared to the control patients. Mortality rates were higher in patients with
anterior myocardial infarction as compared with those with non anterior
myocardial infarction, 6% versus 3%; P =0.08 respectively. 
889 patients randomized
445 patients allocated to GIK therapy 444 patients allocated to standard
444 patients with 30-day follow-up
12 patients lost to
one year follow up
431 with one year follow-up
13 patients lost to
one year follow-up
444 patients with 30-day follow-up
432 with one year follow-upOne-year outcome of GIPS-II                                                                                           
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Table 1: Baseline characteristics, reperfusion therapy and pharmacological treatment of the
patient groups
GIK group  Control group   
Variables                                                          (n=444)                        (n=445)                         P - v a l u e                                                            
Age (years) ± SD 61.8 ± 12.4 61.2 ± 12.3 0.51
Age > 60 years, n (%) 242 (55%) 243 (55%) 0.98
Men n (%) 326 (73%) 329 (74%) 0.86
Previous MI n (%) 37 (8%) 54 (12%) 0.06
Previous PCI, n (%) 27 (6%) 48 (11%) 0.01
Previous CABG, n (%) 6 (1%) 11 (3%) 0.22
Diabetes, n (%) 41 (9%) 46 (10%) 0.57
Diabetes using insulin, n (%) 12 (3%) 10 (2%) 0.66
Hypertension, n (%) 146 (33%) 125 (28%) 0.13
Positive family history 190 (46%) 201 (48%) 0.57
Systolic blood pressure (mmHg) 135.3 ± 25.7 132.5 ± 24.0 0.11
Diastolic blood pressure (mmHg) 80.5 ± 15.9 79.0 ± 15.0 0.18
Anterior infarction, n (%) 210 (48%) 172 (39%) 0.01
Ischemic time, mean± SD 229 ± 143 220 ± 112 0.31
Reperfusion therapy, n (%)  418 (94%) 426 (96%) 0.28
            Primary PCI, n (%) 391 (88%) 387 (87%)
            Rescue PCI, n (%) 23 (6%) 26 (6%)
            Thrombolysis, n (%) 4 (1%) 12 (3%)
Reperfusion successful 395 (95%) 404 (95%) 0.83
Mean glucose on admission (mmol/L) 8.5 ± 2.8 8.3 ± 2.5 0.51
Discharge medication
Aspirin, n (%)                                               422 (95%)                 415 (93%)                    0.26
Coumadin, n (%)                                          17 (4%)                      19 (4%)                      0.74
Clopidrogel, n (%) 396 (89%) 391 (88%) 0.54
Beta-blocker, n (%) 402 (91%) 384 (86%) 0.048
Statin, n (%) 392 (88%) 387 (87%) 0.55
ACE-I, n (%) 261 (59%) 251 (56%) 0.47
Oral anti-glycaemic agent, n (%) 25 (6%) 28 (6%) 0.68
Insulin, n (%)                                                    12 (3%)                       15 (3%)                       0.56
GIK: glucose insulin potassium, MI: myocardial infarction, PCI: percutaneous coronary
intervention CABG: coronary artery bypass grafting, ACE-i: angiotensin-coverting enzyme
inhibitor.                                                                                                                                                            Chapter 4.2
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Figure 2: Kaplan Meier survival curve
Discussion 
The one year follow-up results of GIPS II show that GIK therapy has no beneficial
clinical effect in patients with STEMI without signs of heart failure treated with
reperfusion therapy. No advantage or deterioration has emerged one year after
enrolment with regard to mortality, recurrent myocardial infarction or
reintervention following treatment with GIK.   
Previous reports on the effect of GIK in STEMI have been conflicting. The meta-
analysis of Fath-Ordoubadi and Beatt showed a benefit of GIK infusion [1].
However, studies included in this meta-analysis were of older date and none of
the patients received reperfusion therapy. Most studies published after this meta-
analysis showed only benefit of GIK in specific subgroups. The ECLA study
suggested a mortality reduction in the sub-group treated with reperfusion therapy
[8]. The
 Glucose-insulin-potassium study-I (GIPS-I) showed clinical benefit of GIK
in STEMI patients without signs of heart failure [3], but the GIPS-II could not
confirm this finding [4]. The CREATE–ECLA study, with a sample size of 20.201
patients, showed only a trend toward a better outcome in the patients (n=1831)
treated with primary PCI [5].
 The only study to date showing a clinical benefit of
glucose-insulin was the DIGAMI study [2]. However, this study included
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hyperglycaemic patients, was primarily aimed at reduction of glucose levels, and
GIK in the acute phase was combined with long-term insulin therapy.
There may be several explanations for the lack of effects of GIK in STEMI.
Experimental evidence suggests a beneficial effect of GIK by shifting myocardial
free fatty acid metabolism towards glucose metabolism. This is less oxygen
consuming and produces less toxic side products [9].
 Furthermore, reperfusion
injury may be reduced by limiting apoptosis of post-ischemic myocardial cells.
However, once adequate reperfusion has been established, GIK may be of only
limited value as maximal myocardial salvage has already taken place. It has been
proposed that
 GIK therapy may delay ischemic necrosis to some degree before
reperfusion, thus lengthening
 the period during which effective myocardial salvage
is possible
 with reperfusion strategies [10].
 Theoretically, GIK may be effective if
initiated before reperfusion. Furthermore, glycometabolic support may only be
beneficial when it is aimed at lowering glucose levels in patients with severe
derangement of glucose metabolism as in DIGAMI [2]. 
On the other hand, side effects of GIK infusion include hyperglycaemia,
hyperkaleamia and fluid overload. This may diminish the potential benefits.
Previous studies have showed that hyperglycemia and hypoglycemia are both
associated with worse short- and long term outcome [11-14]. In addition, insulin
therapy is associated with an increased ADP-induced platelet aggregation [15].
This may, at least in part, contribute to the negative results of studies with GIK in
patients with myocardial infarction. Thus, at least in the current form, there is no
role for GIK in routine practice of patients with STEMI. However, there remain
several issues to be clarified. Administering concentrated GIK through a central
line may diminish adverse effects of fluid overload. Further studies should focus
on the timing of GIK administration with respect to
 the timelines and effectiveness
of reperfusion [16]. 
Conclusion    
                                                                                                                  
In patients with  STEMI without signs of heart failure treated with reperfusion
therapy, GIK therapy offers no clinical benefit at one year. In the current form,
there is no role for GIK in routine practice of patients with STEMI.                                                                                                                                                           Chapter 4.2
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Abstract
Background
Admission hyperglycaemia is associated with an increased risk of mortality after
myocardial infarction. Whether long-term glucose dysregulation (assessed by
HbA1c) is more important than acute hyperglycaemia is unknown. We evaluated
the prognostic value of admission glucose and HbA1c levels in non diabetic
patients with ST-segment elevation acute myocardial infarction (STEMI).
Methods
In 504 unselected, consecutive patients with STEMI, glucose and HbA1c levels
were measured on admission. Glucose was categorized as <11.1 mmol/L (n=
422) and ≥11.1 mmol/L (n=82). HbA1c levels were categorized as <6.0% (n=416)
and ≥6.0% (n=88). Mean follow up was 1.6 ± 0.6 years. 
Results
Baseline characteristics of patients with hyperglycemia on admission were
comparable to those with normoglycemia. However, patients with HbA1c ≥6.0%,
as compared to those with HbA1c<6%, were older, used more often beta blockers
and more frequently had multivessel disease. Thirty-day mortality in the
subsequent glucose categories (<11.1 mmol/L and ≥11.1 mmol) was 4% and 19%
(p <0.001) and in the subsequent HbA1c categories (<6% and ≥6%)5% and 12%
(p=0.03). After multivariable analyses admission glucose (OR 4.91; 95%CI: 2.03-
11.9, p<0.001) but not HbA1c (OR 1.33; 95%CI: 0.48-3.71, p=0.58) was
significantly associated with 30-day mortality. Among 30 day survivors, neither
admission glucose nor HbA1c were predictors of long-term mortality.
Conclusion
Elevated admission glucose is an important predictor of 30-day outcome after
STEMI, while prior long-term glucose dysregulation is a covariate of other high
risk clinical characteristics. Among 30-day survivors neither admission blood
glucose nor HbA1c were predictors of long-term outcome.                                                                                                                                                            Chapter 4.3
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Introduction
In patients with acute coronary syndrome (ACS), up to 40% have impaired blood
glucose levels on admission [1]. This has been associated with increased
mortality, irrespective of diabetic status [2-7]. Recent evidence has shown that
chronic glucose dysregulation, assessed by HbA1c levels, is also of prognostic
value with regard to future cardiovascular disease and congestive heart failure [8].
A previous study with a small sample size (n =146) suggested, however, that
admission blood glucose but not HbA1C predicts short-tem mortality after ACS
[9]. It is unclear whether glucose dysregulation is associated with poor long-term
prognosis among 30-day survivors. 
We aimed to investigate the 30-day and long-term prognostic value of both
admission glucose and HbA1c levels in patients with STEMI.  
Materials and methods  
Patients  
It concerns a single-centre, retrospective, follow up study of unselected patients.
During a period of 22 months, from April 2002 till February 2004 admission
glucose and HbA1c were measured in 504 STEMI patients, none previously
known with diabetes mellitus. If patients revisited our hospital with one ore more
re-infarctions during the study period, only the first visit was recorded. Data from
the patient's medical record were collected in a dedicated database. 
Laboratory measurements
HbA1c was measured using a high-performance liquid affinity chromatography
(HPLC) (Primus GLC 385). This method has an inter assay coefficient of variation
of 0.51%. Glucose was measured by a hexokinase method using a Modular PPE
module device (Roche analytics). 
Definitions of clinical diagnosis
STEMI was defined as the presence of chest pain, an electrocardiogram with ST-
segment elevation of more than 1 mm (0.1 mV) in two or more contiguous leads
and a subsequent rise of CK-MB of more than 6% of total CK, whenever CK was
above 200 U/l (men) or above 170 U/l (women). Previous coronary artery disease
was defined as history of myocardial infarction, coronary artery bypass grafting
(CABG) or percutaneous coronary intervention (PCI). Diabetes was defined as
the use of insulin or glucose lowering medication on admission or a diet for
diabetes documented in medical history. Hyperglycemia was defined as glucose
≥11.1 mmol/L based on non-fasting cut-off values for hyperglycemia from theDysglycaemia in STEMI                                                                                                  
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guidelines of American Diabetic Association [10]. A HbA1c ≥6.0% was considered
as elevated HbA1c [11]. Follow-up information with regard to mortality status was
obtained in August 2005. All outpatients reports were reviewed and general
practitioners were contacted by phone. In order to distinguish the short- term and
long-term effects admission glucose and HbA1c, long-term outcome was
assessed only among 30-day survivors. 
Statistical Analysis 
Statistical analysis was performed using SPSS 12.0. Differences between group
means were tested by two-tailed Student's t-test. A Chi-square statistic was
calculated to test differences between proportions, with calculation of relative
risks and exact 95% confidence intervals. The Fisher exact test was used when
the expected value of cells was smaller than 5. Statistical significance was
defined as a p-value of less than 0.05. Admission glucose was included as a
categorical variable (<11.1 mmol/L and ≥11.1 mmol/L) variable. HbA1c levels
were included as a categorical variable (<6.0% and ≥6.0%) variable. Cox
proportional-hazards regression models were used to estimate hazard ratios of
clinical variables with regard to mortality.  
Results
During the study period, 587 patients with STEMI were admitted to our hospital, of
whom 504 (86%) without previously diagnosed diabetes. Mean age was 63 ± 13
years and 72% were male. 474 patients (94%) underwent immediate coronary
angiography, and percutaneous intervention was performed in 428 (85%) of the
patients. There were 82 patients (16%) with hyperglycemia and 88 patients (17%)
with HbA1c ≥ 6.0%. Of the 82 patients with hyperglycemia 29 patients (35%) had
also elevated HbA1c, compared to 53 patients (14%) in those with
normoglycaemia (p< 0.001). Baseline characteristics of patient groups based on
glucose and HbA1c categories are shown in Table 1 and Table 2 respectively. 
Patients with hyperglycemia were comparable to those with admission glucose
<11.1 mmol/L, but had less often sinus rhythm and higher HbA1c levels (Table1).
Patients with HbA1c ≥6%, as compared to those with HbA1c <6%, were
significantly older, had a higher prevalence of previous cerebrovascular disease,
more often used beta-blockers and more often had multivessel diseases.                                                                                                                                                            Chapter 4.3
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Table 1: Baseline, angiography and outcome according to admission glucose
Variable                                  n          Glucose <11.1        n              Glucose ≥ 11.1    P-value
Age 422 63 ± 13 82 64 ± 12 0.64
Male 422 308 (73%) 82 54 (66%) 0.19
SBP
a 360 129 ± 24 63 126 ± 30 0.36
DBP
b 360 79 ± 16 63 76 ± 20 0.32
History of
MI
c 419 56 (13%) 81 8 (10%) 0.39
PCI
d 418 34 (8%) 81 6 (7%) 0.83
CABG
e 418 19 (5%) 81 1 (1%) 0.22
CVA
f 419 11 (3%) 81 1 (1%) 0.70
Hypertension 353 99 (28%) 63 25 (40%) 0.06
Hyperlipidemia 357 82 (23%) 64 16 (25%) 0.72
Family CAD
g 353 142 (40%) 63 27 (43%) 0.70
Smoke 353 187 (53%) 63 26 (41%) 0.09
Anterior infarct location 412 185 (45%) 80 39 (49%) 0.53
CAG
h 422 406 (96%) 72 75 (92%) 0.06
1-VD
i 396 231 (58%) 72 44 (61%) 0.81
≥ 2-VD 396 165 (42%) 72 28 (39%) 0.81
TIMI
j flow pre-PCI 0 380 225 (59%) 69 37 (54%) 0.15
TIMI flow post-PCI 3 371 342 (92%) 67 59 (88%) 0.26
Glucose 422 7.9 ± 1.4 82 14 ± 3.0 < 0.001
HbA1c 422 5.6 ± 0.4 82 6.1 ± 1.1 < 0.001
Mortality
       30-day
       Long-term 
415
398
17 (4%)
17 (4%)
81
66
15(19%)
3 (5%)
<0.001
0.92
a: systolic blood pressure, b: DBP: diastolic blood pressure, c: myocardial infarction, d:
percutaneous coronary interventions, e: coronary artery bypass grafting, f: cerebrovascular
accident, g: CAD: coronary artery disease, h: coronary angiography, i:VD:  vessel disease, j:
Thrombolysis In Myocardial Infarction
Outcome
On discharge eight patients were treated with glucose lowering medication.
Follow-up was complete in 496 (98%) patients, with a mean duration of 1.6 ± 0.6
years. Dysglycaemia in STEMI                                                                                                  
146
Table 2: Baseline, angiography and outcome according to HbA1c
Variable                                  n          HbA1C <6%            n             HbA1C≥6%           P-Value
Age 416 62 ± 14 88 68 ± 11 < 0.001
Male 416 296 (71%) 88 66 (75%) 0.46
SBP
a 348 127 ± 24 75 133 ± 28 0.059
DBP
b 348 78 ± 17 75 80 ± 18 0.35
History of
MI
c 412 51 (12%) 88 13 (15%) 0.54
PCI
d 411 31 (8%) 88 9 (10%) 0.40
CABG
e 411 18 (4%) 88 2 (2%) 0.55
CVA
f 412 7 (2%) 88 5 (6%) 0.027
Hypertension 348 99 (28%) 68 35 (37) 0.17
Hyperlipidemia 353 80 (23%) 68 18 (27%) 0.50
Family CAD
g 348 142 (41%) 68 27 (40%) 0.87
Smoke 348 175 (51%) 68 37 (54%) 0.056
Anterior infarct location 408 188 (45%) 84 41 (49%) 0.58
CAG
h 416 400 (96%) 88 81 (92%) 0.09
1-VD
i 391 241 (62%) 77 34 (44%) 0.028
≥ 2-VD 391 150 (38%) 77 43 (56%) 0.028
TIMI
j flow pre-PCI 0 379 227 (60%) 69 35 (51%) 0.053
TIMI flow post-PCI 3 371 341 (92%) 67 60 (90%) 0.52
Glucose 416 8.6 ± 2.6 88 10.4 ± 3.6 < 0.001
HbA1c 416 5.5 ± 0.2 88 6.6 ± 0.9 < 0.001
Mortality
      30-day 
      Long-term
408
388
22 (5%)
15 (4%)
86
76
10 (12%)
5 (7%)
0.03
0.23
a: systolic blood pressure, b: DBP: diastolic blood pressure, c: myocardial infarction, d:
percutaneous coronary interventions, e: coronary artery bypass grafting, f : cerebrovascular
accident , g CAD: coronary artery disease, h: coronary angiography, i:.VD:  vessel disease, j:
Thrombolysis In Myocardial Infarction.
30-day mortality
At 30-day period 32 patients (7%) had died. Patients who died during follow up
were older, more often had a history of stroke, less often were smokers and less
often had a positive family history. Of the patients with a glucose <11.1 mmol/L,
17 patients (4%) died compared to 15 patients (19%) with hyperglycemia (p
<0.001).                                                                                                                                                            Chapter 4.3
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Mortality curves of the two patient groups according to admission glucose are
shown in Figure 1. Patients with an HbA1c <6.0% had a mortality of 22 (5%)
compared to 10 (12%) in patients with an HbA1c of ≥6.0 (p= 0.03). Mortality
curves of the patient groups according to HbA1c level are shown in Figure 2. 
Long term outcome among 30 day survivors 
Long-term mortality, among 30-day survivor, in the subsequent glucose
categories (<11.1 mmol/L and ≥11.1 mmol) was 4% and 5% (p=0.92). In patients
with HbA1c of <6.0% long-term mortality was 4% compared to 7% in patients with
a HbA1c ≥6.0% (p=0.23).
Multivariate analysis
To investigate whether the association between elevated glucose levels, HbA1c
levels and 30-day outcome were independent of the differences in the baseline
characteristics, multivariate analysis was performed. Included variables were age,
gender, multivessel disease and HbA1c. Because there was a significant
association between HbA1c and glucose, they were separately included in the
multivariate analysis. Independent predictors of 30-day mortality were increased
age (HR 1.04 per year; 95%CI: 1.01-1.07, p =0.013) and elevated admission
glucose (OR 4.91; 95%CI: 2.03-11.9, p< 0.001). An elevated HbA1c level was not
significantly associated with a higher mortality (OR: 1.33; 95%CI: 0.48 -3.71, p
=0.58).Dysglycaemia in STEMI                                                                                                  
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Discussion
This study evaluated the prognostic value of admission glucose and HbA1c in
patients with STEMI. Elevated glucose levels on admission were a strong and
independent predictor of 30-day mortality. Elevated HbA1c was also associated
with a worse prognosis but this was not an independent predictor of mortality.
Neither admission glucose nor HbA1c were predictors of long term mortality.
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Figure1: 30-day mortality according to admission glucose
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Prognostic value of HbA1c 
HbA1c is an easy marker of long-term glucose regulation, unmasking also minor
glycometabolic disease, such as impaired glucose tolerance, impaired fasting
glucose or metabolic syndrome [12-14]. Previous studies have shown that an
elevated HbA1c is associated with increased cardiovascular risk in patients with
and without diabetes [15,16]. However, other studies found no link between the
chronic glycometabolic states and outcome in patients with acute myocardial
infarction and diabetes mellitus [9,17]. In our study patients with an elevated
HbA1c were older, more often had a history of CVA, used more often a beta
blocker on admission and more often had multivessel disease. However, HbA1c
≥6.0% was not a predictor of mortality. This is consistent with a previous small
sample size study [9]. 
Prognostic value of admission glucose
A number of reports have shown the association between elevated admission
glucose and poor outcome in patients with myocardial infarction or unstable
angina [2,8]. This adverse association may be independent of other clinical
prognostic factors [18,19], also in the setting of reperfusion therapy and even after
correction for HbA1c levels [6,9,20]. 
Elevated glucose is not only a symptom of glucose dysregulation, but also of
stress and a more high risk patient population. It has been shown that higher
admission glucose is associated with a higher Killip class, a larger infarct size and
a lower ventricular function [20]. Thrombotic properties of platelets are increased
in a hyperglycemic environment and this can result in additional cardiovascular
complications [21]. Furthermore, elevated glucose levels are accompanied by
increased levels of free fatty acids (FFA) [22]. These FFA may increase infarct
size, compromise myocardial performance during acute coronary syndromes and
reduce endothelium derived vasodilatation in myocardial tissue limiting
myocardial reperfusion [23-25]. In addition, hyperglycemic-induced endothelial
dysfunction, hypercoagulability, platelet dysfunction, and vascular smooth muscle
dysfunction may also contribute to the worse outcome in STEMI patients with
hyperglycemia on admission [26-30]. 
In the current study we found no relation between admission glucose and long-
term outcome among 30-day survivors. A possible explanation is that glucose
levels drops after the acute phase of myocardial infarction, which is shown to be
associated with an improved outcome [31]. This drop in glucose levels may at
least partially due to the drop in stress hormones after the acute phase of
myocardial infarction [32]. Oswald et al showed that stress hormones are main
determinants of plasma glucose in non-diabetic patients with acute myocardialDysglycaemia in STEMI                                                                                                  
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infarction [33]. Others have reported the proportional release of stress hormones
to the severity of myocardial infarction [34]. 
In our study, there were no major differences in baseline characteristics according
to admission glucose. However, elevated glucose levels on admission, but not
chronic glucose dysregulation, were a strong and independent predictor of 30-day
term mortality. These findings are similar to those reported in diabetes [35]. 
Conclusion 
In patients with STEMI, elevated admission blood glucose is an important
independent predictor of 30-day outcome, while elevated HbA1c reflects a more
high risk patient population. Among 30-day survivors neither admission blood
glucose nor HbA1c were predictors of long-term outcome.                                                                                                                                                            Chapter 4.3
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Summary and Conclusions
The aim of the studies reported in this thesis was to evaluate the prognosis after
myocardial infarction in daily clinical practice, to identify markers that are
associated with worse outcome and to provide possible therapeutic options that
may improve outcome. 
Chapter 2 describes (Chapter 2.1) the prognosis after ST elevation myocardial
infarction (STEMI) as well as non-ST elevation myocardial infarction (non-STEMI)
in an unselected patient population. Non-STEMI patients have a less favourable
outcome as compared to STEMI. The worse outcome is mainly due to patient
characteristics and treatment strategy. In Chapter 2.2 we reported the shift from
clinical trial to clinical practice in performing primary percutaneous coronary
intervention (PCI) for patients with STEMI in our hospital. We show that the
number of PCIs has increased dramatically, from 178/year to more than 600/year
from 1994 to 2004. The mean age and the proportion of females increased
significantly from 1994 to 2004. Also rates of high-risk patients who underwent
PCI increased significantly. Coronary stenting increased from 2% to 85% of the
PCI’s. At discharge prescription of aspirin, beta blockers, statin and adenosine
diphosphate receptor blockers increased significantly. Despite treating more high
risk patients, major adverse cardiac events and long-term mortality were reduced
from 36.0% to 18.8% and 9% to 4.9%, respectively. In Chapter 2.3 we show that
further improvement of outcome in STEMI patients is achieved by early, pre-
hospital infarct diagnosis, triage and immediate therapy in the ambulance with
direct transportation to the nearest PCI center. Ambulance triage was feasible in
95% of patients and resulted in earlier diagnosis and initiation of therapy and was
independently associated with a better left ventricular function and clinical
outcome, as compared to triage and transportation from a referral non-PCI center.
In  Chapter 2.4 the ELISA-2 trial is described. The ELISA-2 was designed to
compare dual (aspirin, clopidogrel) vs. triple (aspirin, clopidogrel and tirofiban)
antiplatelet pre-treatment in
 patients with non-STEMI who were planned for early
catheterization. A total of 328 patients were randomly assigned to either dual
(n=166) or triple (n=162) antiplatelet therapy. The primary endpoint was
enzymatic infarct size,
 defined as cumulative LDH release (LDHQ48). We found
that treatment with triple antiplatelet therapy was associated with only a small,
non-significant decrease
 of enzymatic infarct size. However, initial TIMI 3 flow of
the culprit vessel was
 more often present in patients pre-treated with triple as
compared to dual antiplatelet
 regimen (67% vs. 47%, respectively). At 30-days,
rates of death or myocardial infarction were 46% and 57% (p=0.052) in the triple
vs. dual antiplatelet group respectively.Summary and conclusions                                                                                              
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Chapter 3.1 describes external validity of clinical trials, based on our own
experiences from daily clinical practice.  In this study we included a total of 583
patients with discharge diagnosis of STEMI. 455 patients (78%) were enrolled in
one of the ongoing clinical trials and 128 were not. We found that patients who
were not enrolled in a clinical trial or registry were significantly older, more often
had a history of previous myocardial infarction and had higher risk profiles.
Patients who were not enrolled, were more often treated conservatively and had a
higher one-year mortality (36% vs. 6%, p<0.001). In Chapter 3.2 we reported
that, despite less extensive ST-segment deviation on the presenting ECG,
patients with circumflex related myocardial infarction have a significantly larger
infarct size and a worse clinical outcome, compared to patients in whom the right
coronary artery is involved. In Chapter 3.3 we found that independent predictors
of elevated cardiac troponin T (>0.05 µg/L)
 on admission
 in patients with STEMI
were high age, anterior myocardial infarction and presentation delay. Troponin
elevation on admission was associated with a worse clinical outcome. 
Chapter 4 focused on glucose mediated therapeutic options in STEMI patients. In
Chapter 4.1 we present the results of the meta-analysis of randomized clinical
trials with glucose-insulin-potassium (GIK) in STEMI (n=26,082). GIK infusion had
no effect on 30-day mortality. The mortality rate was 9.6% in patients who
received GIK compared to 10.2% in controls. Chapter 4.2 reported the 1-year
outcome of Glucose-insulin-potassium-II study (GIPS-II). In the GIPS-II study
STEMI patients without signs of heart failure were randomized to either GIK or
control. The one-year mortality was not significantly different between patients
treated with GIK and the control group, 5.3% vs. 3.9%, p=0.33 respectively.
Chapter 4.3 shows the prognostic value of acute and chronic glucose
dysregulation in non-diabetic patients, treated with primary PCI for STEMI.
Elevated admission blood glucose (≥11.1 mmol/l) was an independent predictor
of 30-day mortality, while chronic glucose dysregulation was a covariate of high
risk characteristics. Among 30-day survivors neither glucose nor HbA1c were
predictors of long-term outcome.Chapter 5
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Final comments and future directions
Treatment and outcome after myocardial infarction have improved dramatically
last two decades. This is mainly due to the more invasive approach and high
utilization of guideline recommended pharmacotherapy after the acute phase. 
Identifying high-risk patients and early diagnosis 
Despite the improvement in treatment and introducing high quality supporting
devices, outcome of high-risk patients after myocardial infarction is still not
optimal, particularly in those with failed reperfusion and those with poor left
ventricular function. Multifactorial approaches to additional risk stratification and
individual optimal management strategies
 may further improve long-term outcome
of these patients.
The baseline characteristics of patients with STEMI differ from non-STEMI
patients. The latest group has a higher-risk profile on admission. Non-STEMI
patients are often withheld from guideline recommended therapies both during
hospitalization and after discharge. Factors that may contribute to delayed
diagnosis and treatment initiation in non-STEMI are symptoms other than chest
pain on admission, the lack of definitive ECG abnormalities and timing of cardiac
troponin elevation [1-3].
 Furthermore, patients with circumflex artery occlusions
are more likely to present as non-STEMI than as STEMI and might contribute to
the worse outcome in non-STEMI patients [4]. Outcome improvement in non-
STEMI patients may be achieved by a multifactorial approach. Early risk
stratification, using additional diagnostic tools (e.g. echocardiography to
document wall motion abnormalities and posterior ECG in all non-STEMI patients)
and optimal use of antiplatelet and antithrombotics may be useful. Furthermore,
increased use of an invasive strategy may improve outcome [5], although many
aspects of immediate invasive strategy and optimal adjunctive pharmacotherapy
[6] in high-risk non-STEMI patients are to be assessed. 
Time delay to treatment is an important predictor for worse outcome in patients
with ST-elevation myocardial infarction [7]. Early diagnosis and therapy initiation
before transport to a PCI-center by paramedics in the ambulance is feasible and
may improve outcome. The efficacy and safety of the optimal antiplatelet and
antithrombotic combination to be initiated in the ambulance is not yet clear.  Summary and conclusions                                                                                              
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Stents and antiplatelet therapy
The use of stent implantation has increased remarkably last decade. However,
despite the clear reduction of restenosis, the benefits of stenting in terms of death
or reinfarction are not yet clear. Furthermore, preliminary long-term results give
reasons for concern with regard to the safety and cost-effectivity of the drug
eluting stents (DES). Future studies are needed to investigate the long-term
outcome, and to study which patients may have benefit of DES.  
Treatment with clopidogrel was effective in STEMI patients who were treated with
PCI after initial treatment with fibrinolytic therapy [8], however, the duration of
clopidogrel
  therapy post-PCI is not yet clear. Further studies are needed to
investigate the cost-effectivity of long-term clopidogrel use. 
Metabolic support 
Hyperglycemia in the acute phase of myocardial infarction is associated with
worse outcome and optimal glucose metabolism seems to be of importance.
However, recently large randomized trials did not show a beneficial effect of GIK
therapy in STEMI. Late initiation of GIK, GIK-induced hyperglycemia and fluid
overload may explain this failure. Future studies should investigate whether
intensive insulin therapy to maintain blood glucose within a more optimal range is
beneficial, as it seems to be effective among critically ill patients in the intensive
care unit [9].
  Furthermore, timing of GIK administration with respect to
  the
timeliness and effectiveness of reperfusion is a field of interest [10].
  Potential
beneficial effects of glucagon-like peptide-1 (GPL-1) that has insulinomimetic and
insulinotropic actions, should also be further investigated [11].
  Recent studies
showed that GPL-1 stimulates myocardial glucose
  uptake and improves
endothelial dysfunction [12,13].
Technical aspects and multivessel disease 
Distal protection devices to prevent distal embolization have been shown to
reduce CK-MB release in saphenous vein grafts intervention and to improve distal
flow [14]. However, its effect in the setting of STEMI and non-STEMI needs
further investigation in large randomized trials. 
In patients with cardiogenic shock, left ventriclular assist devices, such as Impella,
may improve prognosis [15].
  However, large randomized studies, with longer
assist times are needed to confirm the efficacy of Impella. 
Patients with multivessel disease (MVD) have worse outcome as compared to
those with single vessel disease [16].
 Additional revascularization in patients with
MVD may attenuate the remodelling process, resulting in left ventriclularChapter 5
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functional improvement [17]. The effect of early and optimal additional
revascularization after primary PCI in patients with MVD is a field of interest. 
Prevention of sudden cardiac death
Implantable cardioverter defibrillator (ICD) as primary prevention of sudden
cardiac death may be effective in subgroups after STEMI [18].
  However,
randomized trials comparing ICD with no ICD in selected patients after primary
PCI are lacking. The currently undergoing Defibrillator After Primary Angioplasty
(DAPA) trial assesses the potential benefit of ICD in selected patients with STEMI
treated with primary PCI [19].
Stem cell therapy
Stem cell therapy is also a field of interest. The BOOST trial showed safety,
feasibility and efficacy of the method [20],
 however the exact mode of action is not
yet clear. Many randomized studies are underway to evaluate this novel method
and its exact role in the treatment of ischemic heart failure.
Finally, in making treatment decisions, clinicians should always take into account
limitations and particularly external validity (generalizability) of randomized clinical
trials. Several trials have a low external validity and their have more external
validity as they can include a broader spectrum of daily practice patients [21].
 By
taking the eligible but not recruited patients into account, the generalizability of
studies may increase. By using the Consolidated Standards of Reporting Trials
(CONSORT) statement the quality of reports of randomized trials may improve
further [22].
In conclusion, although treatment and prognosis of myocardial infarction has
improved, there is still room for further improvement in subgroup patients,
especially those not included in randomized trials and those who present with a
non-diagnostic ECG. Many efforts can be and should be made to improve both
treatment and prognosis in these specific subgroups. Summary and conclusions                                                                                              
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Samenvatting en Conclusies
De diagnose hartinfarct wordt gesteld aan de hand van klinische,
elektrocardiografische en biochemische kenmerken. De oorzaak is een plotse
afsluiting van een kransvat. Op basis van het elektrocardiogram (ECG) wordt een
hartinfarct onderverdeeld in een ST-elevatie hartinfarct (STEMI) en een niet–ST-
elevatie hartinfarct (niet-STEMI). In de acute fase is behandeling afhankelijk van
het klinische beeld van de patiënt en het ECG. In dit proefschrift worden diverse
klinische aspecten, behandeling en uitkomsten van patiënten met een hartinfarct
beschreven. 
In Hoofdstuk 1 worden de achtergrond en de opzet van dit proefschrift
beschreven. In Hoofdstuk 2.1 worden de verschillen onderzocht van de
basiskenmerken, de behandeling en de prognose tussen patiënten met een
STEMI en patiënten met een niet-STEMI. De resultaten toonden dat niet-STEMI
patiënten ouder waren, meer co-morbiditeit hadden en vaker medicamenteus
(conservatief) werden behandeld. Na 3 jaar was er in de niet-STEMI groep een
significant hogere sterfte ten opzichte van de STEMI groep (20% versus 12%,
p<0.001). De resultaten van dit onderzoek maken waarschijnlijk dat patiënten met
niet-STEMI bij opname een hoger risicoprofiel hebben en mogelijk worden
onderbehandeld. Een agressievere benadering zou de prognose van niet-STEMI
patiënten gunstig kunnen beïnvloeden. In Hoofdstuk 2.2 wordt 11-jaar Zwolse
ervaring met primaire coronaire interventie (PCI) bij patiënten met een STEMI
beschreven. Het doel is te onderzoeken of er tussen 1994 en 2004 verschillen
zijn ontstaan in basiskenmerken, de behandeling en de uitkomsten bij deze
patiënten. In totaal werden 4732 patiënten geïncludeerd die waren opgenomen
voor een primaire PCI. De gemiddelde leeftijd van de totale populatie was 61 jaar,
11% van de patiënten had diabetes mellitus en 24% waren vrouwen. Ongeveer
de helft van de patiënten werd verwezen uit de omliggende ziekenhuizen. Het
aantal patiënten dat per jaar werd aangemeld voor een primaire PCI steeg van
<200 patiënten in 1994 tot >600 patiënten in 2004. In de periode van 1994 tot
2004 nam de gemiddelde leeftijd en het percentage patiënten ≥75 jaar significant
toe. Er was een duidelijke verandering in de medicatie die bij ontslag werd
voorgeschreven; aspirine, bèta-blokkers en cholesterolverlagende middelen
werden steeds vaker voorgeschreven. Stent implantatie en clopidogrelgebruik
namen eveneens toe in deze periode. Sinds 1994 is de ziekenhuisopnameduur
gedaald van gemiddeld 10,5 dagen in 1994 tot 4,5 dagen in 2004. In dezelfde
periode daalde de ziekenhuissterfte van 6.1% in 1994 tot 1.4% in 2004 (P<0.001)
en trad er een daling op in de combinatie dood, re-infarct en re-PCI na een jaar
(van 36% in 1994 naar 18.8% in 2004, p< 0.001). Samenvating en conclusies                                                                                              
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Hoofdstuk 2.3 beschrijft de haalbaarheid en het belang van pre-hospitale infarct
diagnostiek. Pre-hospitale infarctdiagnostiek werd door een ambulance-
verpleegkundige verricht met gebruikmaking van software voor
elektrocardiografische analyse. Indien de diagnose STEMI werd gesteld, werden
patiënten direct verwezen naar een dottercentrum voor primaire PCI. In het
huidige onderzoek werden STEMI patiënten waarbij pre-hospitale infarct-
diagnostiek werd toegepast (N=209), vergeleken met patiënten (N=258) die
werden verwezen uit omliggende ziekenhuizen. Het doel was te onderzoeken of
door snellere diagnosestelling met behulp van pre-hospitale diagnostiek, de
prognose van STEMI-patiënten verbetert. Bij 59% in de ambulancegroep en 43%
in de verwezen groep werd binnen 90 min na het ontstaan van de klachten
gestart met medicamenteuze therapie. Pre-hospitale infarctdiagnostiek leidde tot
een betere systolische linkerventrikelfunctie, een lagere sterfte (2.1% versus
6.0%, p=0.04) en tot een lager gecombineerd eindpunt van sterfte en re-infarct
(3.6% versus 10.5%, p=0.006). Geconcludeerd kan worden dat pre-hospitale
infarctdiagnostiek en triage goed toepasbare methoden zijn en de prognose van
STEMI-patiënten verbeteren. In Hoofdstuk 2.4 worden de resultaten van het
ELISA-2 onderzoek gerapporteerd. Hierbij werd bij patiënten met niet-STEMI het
additionele effect op enzymatische infarctgrootte en doorstroming van het
bloedvat onderzocht van Glycoproteine IIb//IIIa remmer (tirofiban), bovenop de
standaard therapie met ascal en clopidogrel. Er werden 328 patiënten
geïncludeerd en gerandomiseerd tussen ‘dual therapy’ (ascal en clopidogrel) en
‘triple therapy’ (ascal, clopidogrel en tirofiban). Patiënten kregen een
coronairangiogram binnen 24-48 uur na opname. Triple therapy was
geassocieerd met een iets kleinere enzymatische infarctgrootte en een significant
betere doorstroming van het aangedane bloedvat. Gebaseerd op onze eigen
ervaring beschrijven we in Hoofdstuk 3.1 de verschillen in klinische kenmerken
en uitkomsten tussen 583 patiënten met de ontslagdiagnose STEMI, die wel of
niet deelnamen aan klinische studies. Van alle STEMI-patiënten namen 455
patiënten (78%) wel deel aan één van de klinische studies of registratiestudies,
128 patiënten niet. Patiënten die niet deelnamen aan een klinische studie of
registratie waren ouder, hadden vaker een eerdere hartinfarct doorgemaakt en
hadden in het algemeen een hoger risicoprofiel. De patiënten die niet aan een
studie deelnamen werden vaker conservatief behandeld en hadden een hogere
mortaliteit na 1 jaar in vergelijking met patiënten die wel deelnamen aan een
studie (36% versus 6%, p<0.001). In Hoofdstuk 3.2 onderzochten wij de
verschillen tussen STEMI-patiënten met een hartinfarct dat werd veroorzaakt door
afsluiting van de circumflexarterie (CX) met patiënten met een hartinfarct door
afsluiting van rechtercoronair arterie (RCA). De resultaten laten zien dat ondanks
minder uitgebreide afwijkingen op het elektrocardiogram, de patiënten met eenChapter 6
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CX gerelateerd hartinfarct een significant groter infarct hadden en een slechtere
klinische uitkomst, vergeleken met patiënten met een RCA-gerelateerd
hartinfarct. In Hoofdstuk 3.3 worden de voorspellers van een reeds bij opname
verhoogd cardiaal troponine T (>0.05 ng/L) bij STEMI patiënten onderzocht. De
resultaten laten zien dat een hoge leeftijd, een voorwandinfarct en een late
presentatie onafhankelijke voorspellers zijn van een verhoogde troponine bij
opname. Een verhoogd troponine bij opname was overigens geassocieerd met
een slechtere klinische uitkomst. In Hoofdstuk 4 worden glucosegerelateerde
therapeutische opties bij STEMI-patiënten beschreven. In Hoofdstuk 4.1 worden
de resultaten van een grootschalige meta-analyse van gerandomiseerde studies
met Glucose-Insulin-Potassium (GIK) bij STEMI (n= 26.082) gepresenteerd. De
resultaten laten zien dat GIK geen gunstig effect heeft op mortaliteit na 30 dagen.
Deze was 9.6% in de GIKgroep, versus 10.2% in de controlegroep. In Hoofdstuk
4.2 worden de 1-jaarsresultaten van de Glucose-Insulin-Potassium studie II
(GIPS-II) beschreven. Hierbij werden 889 STEMI-patiënten gerandomiseerd
tussen GIK en controle. Er was geen verschil in 1-jaars mortaliteit tussen GIK- en
controlegroep, 5.3% versus 3.9% respectievelijk, (p =0.33). In Hoofdstuk 4.3
wordt de prognostische waarde onderzocht van een acute en een chronische
glucosedisregulatie (HbA1c) bij niet-diabetische patiënten met STEMI, die een
primaire PCI ondergaan,. De resultaten laten zien dat een verhoogde
glucosespiegel bij opname (≥11.1 mmol/l) een onafhankelijke voorspeller is voor
de mortaliteit na 30 dagen, terwijl een verhoogde HbA1c co-variant is met hogere
risicokenmerken. Bij patiënten die na 30 dagen nog in leven waren, is noch de
glucosespiegel bij opname noch het HbA1c een onafhankelijke voorspeller voor
lange termijn uitkomst. 
Slotopmerkingen en toekomstige ontwikkelingen 
De laatste twee decennia zijn de behandeling en de uitkomst van patiënten met
een hartinfarct aanzienlijk verbeterd. Deze verbetering is vooral te danken aan
een meer invasieve benadering en een betere medicamenteuze behandeling
conform richtlijnen. 
Identificeren van hoogrisicopatiënten en vroege diagnostiek 
Ondanks verbetering van de behandeling en het gebruik bij ondersteunende
hulpmiddelen is de uitkomst van hoogrisicopatiënten nog niet goed genoeg.
Vooral patiënten met een onvoldoende of niet-tijdige reperfusie en/of patiënten
met een slechte linkerventrikelfunctie hebben een ongunstige prognose voor
zowel mortaliteit als morbiditeit. Een multifactoriële benadering door additionele
risicostratificatie en een op het individu toegespitste behandelingstrategie kanSamenvating en conclusies                                                                                              
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leiden tot een verbetering van de langetermijnuitkomsten. De basiskenmerken
van STEMI-patiënten verschillen van die van niet-STEMI patiënten. Bij opname
hebben niet-STEMI patiënten een hoger risicoprofiel. Deze patiënten worden
daarnaast zowel tijdens opname als bij ontslag minder vaak volgens de richtlijnen
behandeld. De factoren die bij niet-STEMI-patiënten kunnen bijdragen tot een
vertraging in het stellen van de diagnose, en dus tot een late initiatie van de
behandeling, zijn onder andere atypische symptomen, het ontbreken van
kenmerkende ECG-afwijkingen en de timing van de troponinestijging. Bovendien
worden patiënten met een achterwandinfarct door een geoccludeerde CX, soms
ten onrechte als een niet-STEMI behandeld. Snelle risico stratificatie, het gebruik
van additionele diagnostische hulpmiddelen (b.v. echocardiogram ter analyse van
wandbewegingsstoornissen, en posterior-ECG bij alle niet-STEMI patiënten) en
een optimale antitrombotische behandeling kunnen een gunstig effect hebben.
Een toenemend gebruik van een invasieve strategie kan waarschijnlijk de
uitkomst van niet-STEMI-patiënten verder verbeteren. Vele aspecten van een
onmiddellijke invasieve strategie en optimale co-medicatie in hoogrisico niet-
STEMI- patiënten moeten echter nog worden onderzocht. 
Een lang tijdsinterval tussen het begin van de klachten en behandeling is een
belangrijke voorspeller voor een ongunstige uitkomst bij patiënten met een
STEMI. Diagnostiek en start van medicamenteuze therapie door ambulance-
verpleegkundigen is goed uitvoerbaar en kan leiden tot een betere prognose. Wat
de optimale combinatie is van antitrombotische middelen die in de ambulance kan
worden geïnitieerd, dient verder bestudeerd te worden. 
Stents en bloedplaatjesremmers
Stentimplantatie is laatste decennia aanzienlijk toegenomen. Ondanks een
duidelijke afname in restenose, is er echter nog geen effect aangetoond van het
gebruik van stents op mortaliteit en reïnfarct. De eerste lange termijn resultaten
van de zogenoemde drug eluting stents (DES) wat sterfte en kosteneffectiviteit
betreft, zijn bovendien niet eenduidig. Verder onderzoek is nodig voor de
evaluatie van langetermijnresultaten en om na te gaan welke patiënten profiteren
van een DES. Behandeling met clopidogrel bleek gunstige effecten te hebben bij
STEMI-patiënten die een PCI ondergingen, na eerdere behandeling met
fibrinolyse. Hoe lang echter na een PCI clopidogrel gecontinueerd moet worden is
vooralsnog onbekend. Meer onderzoek is nodig om de kosteneffectiviteit van
clopidogrelgebruik op lange termijn te evalueren.Chapter 6
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Metabole ondersteuning 
Een verhoogde glucoseconcentratie in de acute fase van het hartinfarct is
geassocieerd met een slechtere prognose. Een optimale glucoseregulatie rond
het infarct kan de prognose waarschijnlijk verbeteren. Recent uitgevoerd,
grootschalig en gerandomiseerd onderzoek  liet echter geen gunstig effect van
GIK zien bij STEMI-patiënten. Het ontbreken van een gunstig effect van GIK kan
onder andere worden verklaard door een late start van GIK, door een GIK-
geïnduceerde hyperglykemie en door vochtbelasting ten gevolge van het GIK-
infuus. Toekomstig onderzoek moet het effect van intensieve insulinetherapie ter
handhaving van een optimale bloedglucoseconcentratie onderzoeken. Een
dergelijke intensieve glucoseregulatie heeft immers bij Intensive Care patiënten
wel een positief effect gehad. Daarnaast is verder onderzoek naar een vroege
toediening van GIK met betrekking tot reperfusie interessant. Potentiële gunstige
effecten van glucagon-like-peptide-1 (GPL-1), moeten ook verder worden
onderzocht. Recente studies lieten zien dat GPL-1 de opname van glucose door
myocardcellen bevordert en endotheeldysfunctie doet afnemen.
Technische aspecten en meertakslijden 
Distale protectie ter preventie van distale embolisatie veroorzaakte in een eerdere
studie een afname van de CK-MB release en een verbetering van de distale
bloeddoorstroming bij een interventie van een venegraft. Grootschalig
gerandomiseerd onderzoek is nodig om de effecten van deze technieken bij
zowel STEMI- als niet-STEMI-patiënten te bestuderen. Bij patiënten met een
cardiogene shock kunnen linkerventrikel- ‘assist devices’, zoals Impella mogelijk
de prognose verbeteren. Ook hier is echter grootschalig onderzoek nodig om de
gunstige werking van Impella te bevestigen. 
Patiënten met meertakslijden hebben een slechtere prognose vergeleken met
patiënten met eentakslijden. Additionele revascularisatie bij patiënten met
meertakslijden kan leiden tot een verbetering van het remodelleringsproces, en
zo tot een verbetering van de linkerventrikelfunctie. Het effect van een vroege en
een optimale revascularisatie na een primaire PCI is een interessant en
belangwekkend onderzoeksterrein.
Preventie van plotse hartdood 
In een subgroep van patiënten na een STEMI kan een Inwendige Cardioverter
Defibrillator (ICD) een plotse hartdood voorkomen. Maar tot op heden is het effect
van een ICD na een primaire PCI nauwelijks onderzocht. De momenteel lopende
’Defibrillator After Primary Angioplasty’ (DAPA)-studie evalueert het eventuele
voordeel van een ICD bij een geselecteerde groep STEMI-patiënten die
behandeld zijn met een primaire PCI. Samenvating en conclusies                                                                                              
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Stamceltherapie 
Stamceltherapie is mogelijk een interessante toekomstige behandeling. De
‘BOOTS’ studie heeft de veiligheid, de toepasbaarheid en de effectiviteit van
stamceltherapie aangetoond. Het exacte werkingsmechanisme is echter nog
onduidelijk. Ondertussen lopen er meerdere klinische studies die de exacte rol bij
de behandeling van patiënten met ischemisch hartfalen evalueren. 
Tot slot, bij het nemen van een beslissing tot behandeling, moeten clinici altijd de
beperkingen en vooral de externe validiteit (generaliseerbaarheid) van klinische
studies in het achterhoofd houden. Vele studies hebben een lage externe
validiteit en de resultaten ervan zijn niet zondermeer te extrapoleren naar de
dagelijkse praktijk. Observationele studies zijn waarschijnlijk beter toepasbaar
dan gerandomiseerde studies wegens inclusie van alle patiënten in de dagelijkse
praktijk.  Het rapporteren van het 'Consolidated Standards of Reporting Trials’
(CONSORT)-schema kan de interpretatie van gerandomiseerde studies verbeteren. 
Concluderend kan gesteld worden dat, hoewel de behandeling en de prognose
van het hartinfarct de laatste decennia is verbeterd, er nog meer pogingen
moeten worden gedaan ter verbetering van de behandeling en de prognose van
specifieke patiënten. Curiculum Vitae
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